datetime,title,source,link,sentiment_class,sentiment_score
11/25/2020 6:25:04 PM,Merck and Biotech’s Swashbuckling Era,InvestorPlace,/news/stocks/swashbuckling-era-merck-mrk-stock-1029839832,neutral,0.9027481079101562
11/30/2020 2:12:00 AM,Biotech Stocks Facing FDA Decision In December 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2020-1029847132,neutral,0.7155784368515015
12/11/2020 2:29:46 PM,"Viatris says, up to 20% of workforce may be impacted in restructure",Seeking Alpha,https://seekingalpha.com/news/3643713-viatris-says-up-to-20-of-workforce-may-be-impacted-in-restructure?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9540942907333374
12/11/2020 2:29:46 PM,Viatris says up to 20% of its workforce may be impacted by restructuring,Seeking Alpha,https://seekingalpha.com/news/3643713-viatris-says-up-to-20-of-workforce-may-be-impacted-restructuring?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9523707032203674
12/11/2020 2:50:42 PM,"Viatris Says Restructuring To Impact 15 Manufacturing Facilities, Up To 20% Of Workforce ",RTTNews,/news/stocks/viatris-says-restructuring-to-impact-15-manufacturing-facilities-up-to-20-of-workforce-1029885463,negative,0.7119461894035339
12/20/2020 1:19:39 PM,"Notable Insider Buys of the Past Week: Mylan, Sonabank, Steak 'n Shake, U-Haul And More",Benzinga,/news/stocks/notable-insider-buys-of-the-past-week-mylan-sonabank-steak-n-shake-u-haul-and-more-1029909485,neutral,0.9066047668457031
12/26/2020 3:15:52 PM,"The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks",Benzinga,/news/stocks/the-week-ahead-in-biotech-dec-27-jan-2-data-releases-regulatory-filings-to-move-stocks-1029919761,neutral,0.6830363869667053
12/31/2020 12:49:45 PM,Viatris biosimilar faces regulatory delay,Seeking Alpha,https://seekingalpha.com/news/3648043-viatris-biosimilar-faces-regulatory-delay?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8477115035057068
12/31/2020 7:19:38 PM,Why Pfizer is the Cheapest Coronavirus Vaccine Play,InvestorPlace,/news/stocks/pfe-stock-pfizer-does-not-include-value-biontech-and-vaccine-1029927517,neutral,0.868235170841217
1/12/2021 4:32:16 PM,"Even In This Market, There Are Better Choices Than Pfizer Stock",InvestorPlace,/news/stocks/better-choices-than-pfe-stock-1029961129,neutral,0.7564706206321716
1/14/2021 5:48:25 PM,Viatris under pressure on conservative outlook,Seeking Alpha,https://seekingalpha.com/news/3651544-viatris-under-pressure-on-conservative-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6317262649536133
1/28/2021 7:20:43 PM,FTC approves final order on conditions for Pfizer spinoff Viatris,Seeking Alpha,https://seekingalpha.com/news/3655734-ftc-approves-final-order-on-conditions-for-pfizer-spinoff-viatris?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6257563233375549
2/1/2021 8:08:03 PM,3 Reasons Pfizer Stock Will Have a Solid 2021,InvestorPlace,/news/stocks/3-reasons-pfizer-stock-will-have-a-solid-2021-1030029507,positive,0.9223460555076599
2/2/2021 10:01:15 AM,7 Pharmaceutical Stocks With Compelling Pipelines,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-with-compelling-pipelines-1030031896,positive,0.9111998677253723
2/19/2021 8:15:51 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3664052-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
2/20/2021 3:36:28 PM,"The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings",Benzinga,/news/stocks/the-week-ahead-in-biotech-j-j-vaccine-adcom-meeting-sarepta-fda-decision-and-plenty-of-earnings-1030104010,neutral,0.8801164627075195
2/22/2021 12:23:29 PM,"Viatris guides 2021 revenue below estimates, initiates dividend",Seeking Alpha,https://seekingalpha.com/news/3664243-viatris-guides-2021-revenue-below-estimates-initiates-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4824621379375458
2/22/2021 1:25:46 PM,"OTIC, VTRS among premarket losers",Seeking Alpha,https://seekingalpha.com/news/3664290-otic-vtrs-among-premarket-losers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.915080189704895
2/22/2021 1:33:27 PM,Viatris Sees FY21 Revenue Below View - Quick Facts ,RTTNews,/news/stocks/viatris-sees-fy21-revenue-below-view-quick-facts-1030107156,negative,0.5637221932411194
3/2/2021 4:02:35 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-2-2021-1030141204,negative,0.545123815536499
3/5/2021 4:50:37 PM,7 Mega-Cap Stocks Standing Above the Fray,InvestorPlace,/news/stocks/7-mega-cap-stocks-standing-above-the-fray-1030155694,positive,0.6427069306373596
3/8/2021 1:13:12 PM,Struggling defensive sectors losing even more appeal ahead of more stimulus: At the Open,Seeking Alpha,https://seekingalpha.com/news/3670158-struggling-defensive-sectors-losing-even-more-appeal?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.882236659526825
3/8/2021 1:20:46 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1030159064,neutral,0.7998325824737549
3/8/2021 1:30:21 PM,Viatris : FDA Grants Tentative Approval Of Budesonide/formoterol Fumarate Dihydrate Products ,RTTNews,/news/stocks/viatris-fda-grants-tentative-approval-of-budesonide-formoterol-fumarate-dihydrate-products-1030159079,positive,0.9207747578620911
3/8/2021 4:04:40 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-8-2021-1030160061,negative,0.584946870803833
3/8/2021 8:29:29 PM,Viatris announces tentative FDA approval for generic Symbicort,Seeking Alpha,https://seekingalpha.com/news/3670410-viatris-announces-tentative-fda-approval-for-generic-symbicort?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7065110206604004
4/15/2021 6:15:07 PM,10 Stocks to Buy for Your $5K Robinhood Portfolio,InvestorPlace,/news/stocks/10-stocks-to-buy-5k-robinhood-portfolio-1030310321,neutral,0.9261453747749329
5/8/2021 3:01:29 PM,Here's what Wall Street expects from Viatris's earnings report,Markets Insider Automation,/news/stocks/viatris-q1-quarterly-earnings-preview-1030404671,neutral,0.9087100625038147
5/9/2021 4:20:33 PM,"The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-9-15-heron-apellis-fda-decisions-presentations-and-earnings-1030405849,neutral,0.944421648979187
5/10/2021 11:01:10 AM,"Viatris EPS beats by $0.12, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3693688-viatris-eps-reports-q1-results?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5679944157600403
5/10/2021 11:01:15 AM,Viatris declares $0.11 dividend,Seeking Alpha,https://seekingalpha.com/news/3693685-viatris-declares-0_11-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8914501070976257
5/10/2021 11:51:43 AM,Viatris Q1 tops forecast; declares inaugural quarterly dividend of $0.11,Seeking Alpha,https://seekingalpha.com/news/3693745-viatris-q1-tops-forecast-declares-inaugural-quarterly-dividend-of-011?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8527255058288574
5/10/2021 1:26:34 PM,EARNINGS SUMMARY: Details of Viatris Inc. Q1 Earnings Report,RTTNews,/news/stocks/earnings-summary-details-of-viatris-inc-q1-earnings-report-1030408674,neutral,0.9247184991836548
5/10/2021 2:17:27 PM,"Viatris Reaffirms FY21 Revenue Outlook, Declares Dividend - Quick Facts ",RTTNews,/news/stocks/viatris-reaffirms-fy21-revenue-outlook-declares-dividend-quick-facts-1030409051,positive,0.799691379070282
5/12/2021 7:41:15 PM,Viatris earns mixed views from analysts despite more clarity in Q1 results,Seeking Alpha,https://seekingalpha.com/news/3695446-viatris-earns-mixed-views-from-analysts-despite-more-clarity-in-q1-results?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9464383721351624
6/9/2021 10:00:22 AM,Pfizer Is Still One of the Healthcare Sector’s Best Dividend Yielders,InvestorPlace,/news/stocks/pfe-stock-is-still-one-of-the-health-care-sectors-best-dividend-yielders-1030506713,positive,0.8141419887542725
6/15/2021 2:16:37 PM,"Bullish on AstraZeneca cancer drug, Cronos MSO stake not a big deal, and more in analyst action",Seeking Alpha,https://seekingalpha.com/news/3706440-bullish-on-astrazeneca-cancer-drug-cronos-mso-stake-not-a-big-deal-and-more-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7752115726470947
6/15/2021 4:24:55 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-15-2021-1030524604,negative,0.571738600730896
6/24/2021 3:04:22 AM,Mylan Wins Summary Judgment Rulings In Kansas EpiPen Auto-Injector Class Action ,RTTNews,/news/stocks/mylan-wins-summary-judgment-rulings-in-kansas-epipen-auto-injector-class-action-1030549069,positive,0.4707706868648529
6/24/2021 2:12:04 PM,"The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-spikes-on-alzheimer-s-drug-regulatory-filing-plan-applied-genetics-arcus-issue-data-readouts-adcom-test-awaits-incyte-monte-rosa-prices-ipo-1030550889,neutral,0.93064284324646
7/1/2021 6:50:48 PM,Eisai and Lilly among top H1 gainers in big pharma; Viatris and Merck trail,Seeking Alpha,https://seekingalpha.com/news/3712052-eisai-and-lilly-among-top-h1-gainers-in-big-pharma-as-viatris-and-merck-trail?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8283566832542419
7/8/2021 7:59:00 PM,"Viatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021",PR Newswire,/news/stocks/viatris-inc-to-release-second-quarter-2021-financial-results-on-aug-9-2021-1030591033,neutral,0.9289260506629944
7/15/2021 5:25:04 PM,Pfizer to pay $345M to settle litigation over alleged EpiPen price gouging scheme,Seeking Alpha,https://seekingalpha.com/news/3715670-pfizer-to-pay-345m-to-settle-litigation-over-alleged-epipen-price-gouging-scheme?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7482548952102661
7/27/2021 1:47:32 PM,Viatris : Mylan Wins Dismissal Of Kansas EpiPen Direct Purchaser Case ,RTTNews,/news/stocks/viatris-mylan-wins-dismissal-of-kansas-epipen-direct-purchaser-case-1030649704,negative,0.8466120362281799
7/29/2021 5:29:00 AM,Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes,PR Newswire,/news/stocks/viatris-inc-and-biocon-biologics-receive-historic-approval-for-first-interchangeable-biosimilar-semglee-insulin-glargine-yfgn-injection-for-the-treatment-of-diabetes-1030659306,positive,0.8969290852546692
7/29/2021 5:43:43 AM,Viatris Gets FDA Approval For Interchangeable Biosimilar Semglee For Diabetes Treatment ,RTTNews,/news/stocks/viatris-gets-fda-approval-for-interchangeable-biosimilar-semglee-for-diabetes-treatment-1030659353,positive,0.925417423248291
7/29/2021 2:18:48 PM,"The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-disappointing-q2-atreca-falls-on-data-fda-nod-for-viatris-nuvalent-icosavax-ipos-1030662210,negative,0.9680227041244507
8/6/2021 2:07:09 PM,Notable earnings before Monday's open,Seeking Alpha,https://seekingalpha.com/news/3727030-notable-earnings-before-mondays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8824691772460938
8/7/2021 3:01:21 PM,What Wall Street expects from Viatris's earnings,Markets Insider Automation,/news/stocks/viatris-stock-price-q2-earnings-preview-1030703441,neutral,0.929730236530304
8/8/2021 4:11:24 PM,"The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-aug-8-14-jazz-pharma-fda-decision-earnings-deluge-and-ipos-in-the-spotlight-1030704359,negative,0.9279987215995789
8/9/2021 12:59:00 PM,Viatris Reports Strong Second Quarter Results,PR Newswire,/news/stocks/viatris-reports-strong-second-quarter-results-1030708096,positive,0.9488210082054138
8/9/2021 1:02:45 PM,EARNINGS SUMMARY: Details of Viatris Inc. Q2 Earnings Report,RTTNews,/news/stocks/earnings-summary-details-of-viatris-inc-q2-earnings-report-1030708016,neutral,0.9194756150245667
8/9/2021 1:19:34 PM,"Viatris Boosts FY21 Revenue Outlook, Declares Dividend - Quick Facts ",RTTNews,/news/stocks/viatris-boosts-fy21-revenue-outlook-declares-dividend-quick-facts-1030708141,positive,0.9344899654388428
9/15/2021 2:34:09 PM,Why Are Theravance Bio Shares Plummeting Premarket Today?,Benzinga,/news/stocks/why-are-theravance-bio-shares-plummeting-premarket-today-1030801576,negative,0.8619145750999451
9/17/2021 4:35:24 PM,7 Spinoff Stocks to Buy That Are Set to Outperform Their Parents,InvestorPlace,/news/stocks/7-spinoff-stocks-to-buy-that-are-set-to-outperform-their-parents-1030807715,positive,0.6435421705245972
9/27/2021 10:00:45 AM,Pfizer Stock: Vaccine Crown Not Enough as Profit King Status Comes Next,InvestorPlace,/news/stocks/pfizer-stock-vaccine-crown-not-enough-as-profit-king-status-comes-next-1030825066,neutral,0.42333874106407166
10/11/2021 1:30:00 PM,Viatris Named Fifth on Fortune's Change the World List,PR Newswire,/news/stocks/viatris-named-fifth-on-fortune-s-change-the-world-list-1030855821,neutral,0.7482827305793762
10/20/2021 5:37:00 PM,Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary,PR Newswire,/news/stocks/viatris-first-ever-interchangeable-insulin-biosimilar-preferred-on-express-scripts-largest-formulary-1030882562,positive,0.5301193594932556
11/5/2021 2:45:59 PM,Notable earnings before Monday's open,Seeking Alpha,https://seekingalpha.com/news/3766190-notable-earnings-before-mondays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8824691772460938
11/6/2021 5:12:10 AM,Viatris Q3 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3766233-viatris-q3-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.880113959312439
11/7/2021 3:01:13 PM,Here's what to expect from Viatris's earnings,Markets Insider Automation,/news/stocks/viatris-stock-q3-earnings-preview-1030944885,neutral,0.9386283755302429
11/8/2021 12:01:47 PM,"Viatris EPS of $0.26, raises guidance",Seeking Alpha,https://seekingalpha.com/news/3766624-viatris-eps-of-026-raises-guidance?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8292227387428284
11/8/2021 12:59:00 PM,"Viatris Reports Strong Third Quarter Results, Raises 2021 Financial Guidance and Announces Virtual Investor Event on January 7, 2022",PR Newswire,/news/stocks/viatris-reports-strong-third-quarter-results-raises-2021-financial-guidance-and-announces-virtual-investor-event-on-january-7-2022-1030948467,positive,0.7168677449226379
11/8/2021 1:04:37 PM,Viatris Inc. Q3 sales increase,RTTNews,/news/stocks/viatris-inc-q3-sales-increase-1030948502,positive,0.9038768410682678
11/8/2021 1:08:21 PM,Viatris tightens 2021 revenue guidance; growth momentum in net sales cools,Seeking Alpha,https://seekingalpha.com/news/3766697-viatris-tightens-2021-revenue-guidance-growth-momentum-in-net-sales-cools?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4854608476161957
11/8/2021 2:24:25 PM,"The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-nov-7-nov-13-earnings-taper-off-multiple-conference-presentations-ipos-and-more-1030949001,negative,0.9685659408569336
11/10/2021 10:51:39 PM,Patent board to review Regeneron Eylea patents following Viatris challenge,Seeking Alpha,https://seekingalpha.com/news/3769249-patent-board-to-review-regeneron-eylea-patents-following-viatris-mylan-challenge?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9103145599365234
11/11/2021 12:59:00 PM,"Viatris Donates $1 Million as Founding Champion to New Orleans-based SBP's ""Got Your Back"" fund in Support of Housing Solutions for Veterans in Disaster-Impacted Communities",PR Newswire,/news/stocks/viatris-donates-1-million-as-founding-champion-to-new-orleans-based-sbp-s-got-your-back-fund-in-support-of-housing-solutions-for-veterans-in-disaster-impacted-communities-1030964631,positive,0.7809097766876221
11/16/2021 12:59:00 PM,Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection,PR Newswire,/news/stocks/viatris-and-biocon-biologics-announce-launch-of-interchangeable-semglee-insulin-glargine-yfgn-injection-and-insulin-glargine-insulin-glargine-yfgn-injection-1030979735,neutral,0.49379950761795044
11/16/2021 1:17:32 PM,"Viatris, Biocon Launch Biosimilar Products Interchangeable For LANTUS - Quick Facts ",RTTNews,/news/stocks/viatris-biocon-launch-biosimilar-products-interchangeable-for-lantus-quick-facts-1030979887,neutral,0.7903149127960205
11/16/2021 7:09:28 PM,"Paulson & Co. drops Discovery, reduces stake in Viatris, raises position in DiDi Global",Seeking Alpha,https://seekingalpha.com/news/3771587-paulson-co-drops-discovery-reduces-stake-in-viatris-raises-position-in-didi-global?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.4421565532684326
11/18/2021 12:59:00 PM,Viatris to Participate in Evercore ISI 4th Annual HealthCONx Conference,PR Newswire,/news/stocks/viatris-to-participate-in-evercore-isi-4th-annual-healthconx-conference-1030987533,neutral,0.7425994277000427
11/19/2021 4:35:39 PM,Viatris goes ex-dividend on Monday,Seeking Alpha,https://seekingalpha.com/news/3772957-viatris-goes-ex-dividend-on-monday?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6663848757743835
11/22/2021 11:00:16 AM,7 Stocks to Buy for Their Resistance to the 6.2% Monthly Inflation,InvestorPlace,/news/stocks/7-stocks-to-buy-for-their-resistance-to-the-6-2-monthly-inflation-1030994239,positive,0.45518118143081665
11/30/2021 7:29:27 PM,7 Drug Stocks to Buy Now While They’re Still on Sale,InvestorPlace,/news/stocks/7-drug-stocks-to-buy-now-while-theyre-still-on-sale-1031013701,neutral,0.8935650587081909
12/1/2021 12:59:00 PM,Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent,PR Newswire,/news/stocks/viatris-wins-federal-circuit-court-appeal-upholding-district-court-decision-invalidating-biogen-s-tecfidera-patent-1031015378,negative,0.5287079215049744
12/1/2021 1:21:34 PM,Viatris Wins Federal Circuit Court Appeal On Biogen's Tecfidera Patent - Quick Facts ,RTTNews,/news/stocks/viatris-wins-federal-circuit-court-appeal-on-biogen-s-tecfidera-patent-quick-facts-1031015535,positive,0.5474846959114075
12/1/2021 2:41:54 PM,"The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-backs-merck-s-oral-covid-19-treatment-regulatory-setbacks-for-cti-biopharma-bioxcel-favorable-ruling-for-viatris-in-tecfidera-patent-case-1031016008,positive,0.928840160369873
12/2/2021 6:44:27 PM,"Regeneron: Surfing on Covid, With More Under the Surface",InvestorPlace,/news/stocks/regn-stock-regeneron-surfing-on-covid-1031021097,neutral,0.9220339059829712
12/6/2021 2:00:00 PM,Viatris Named by Newsweek as One of America's Most Responsible Companies,PR Newswire,/news/stocks/viatris-named-by-newsweek-as-one-of-america-s-most-responsible-companies-1031025982,positive,0.7337847948074341
12/6/2021 4:51:13 PM,New study shows Viagra can lower risk of Alzheimer’s disease,Seeking Alpha,https://seekingalpha.com/news/3777432-new-study-shows-viagra-can-lower-risk-of-alzheimers-disease?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8904270529747009
12/9/2021 1:16:55 PM,India's Biocon said in talks to merge its biologics unit with Mylan's biosimilar business,Seeking Alpha,https://seekingalpha.com/news/3778655-indias-biocon-said-in-talks-to-merge-its-biologics-unit-with-mylans-biosimilar-business?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8694543838500977
12/9/2021 5:02:48 PM,Viatris to unlock value with Biocon deal - Evercore,Seeking Alpha,https://seekingalpha.com/news/3778807-viatris-to-unlock-value-with-biocon-deal-evercore?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.585067868232727
12/13/2021 2:47:03 PM,"Nasdaq Biotechnology rejig: VTRS, NVCR among added, KALA, VYNE among deleted",Seeking Alpha,https://seekingalpha.com/news/3779527-nasdaq-biotechnology-rejig-vtrs-nvcr-among-added-kala-vyne-among-deleted?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8636766672134399
12/15/2021 6:07:29 PM,7 of the Best Value Stocks for 2022 to Buy Now,InvestorPlace,/news/stocks/7-of-the-best-value-stocks-for-2022-you-should-buy-now-1031048255,neutral,0.8675443530082703
12/17/2021 11:15:00 PM,Viatris to Move its Investor Event Previously Scheduled for January 7 to no Later Than February 28 When the Company Expects to Report its Fourth Quarter 2021 Results,PR Newswire,/news/stocks/viatris-to-move-its-investor-event-previously-scheduled-for-january-7-to-no-later-than-february-28-when-the-company-expects-to-report-its-fourth-quarter-2021-results-1031054304,neutral,0.9041481614112854
12/30/2021 2:30:00 AM,Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations,PR Newswire,/news/stocks/viatris-wins-court-decisions-on-sanofi-appeals-of-lantus-patent-invalidations-1031070348,negative,0.5833982825279236
12/30/2021 2:44:51 AM,Viatris Wins Court Decisions On Sanofi Appeals Of Lantus Patent Invalidations ,RTTNews,/news/stocks/viatris-wins-court-decisions-on-sanofi-appeals-of-lantus-patent-invalidations-1031070351,negative,0.4867475926876068
1/3/2022 7:14:06 PM,7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now,InvestorPlace,/news/stocks/7-of-the-best-cheap-stocks-under-20-for-2022-to-buy-now-1031074754,neutral,0.6870387196540833
1/6/2022 12:14:06 PM,Viatris raises dividend by ~9% to $0.12/share,Seeking Alpha,https://seekingalpha.com/news/3785732-viatris-raises-dividend-by-9-to-012share?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9102150201797485
1/6/2022 12:56:30 PM,7 Pharmaceutical Stocks That Could Make You Rich,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-that-could-make-you-rich-1031081342,neutral,0.9103521108627319
1/6/2022 1:00:00 PM,"Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend",PR Newswire,/news/stocks/viatris-announces-9-dividend-increase-fourth-consecutive-quarterly-dividend-1031081192,positive,0.9462251663208008
1/20/2022 10:34:20 AM,Mylan Recalls Certain Semglee(insulin Glargine) Prefilled Pens ,RTTNews,/news/stocks/mylan-recalls-certain-semglee-insulin-glargine-prefilled-pens-1031115194,neutral,0.7030009627342224
2/3/2022 10:42:21 PM,Viatris gets FDA nod for 1st generic version of AbbVie's dry eye therapy Restasis,Seeking Alpha,https://seekingalpha.com/news/3795887-viatris-gets-fda-nod-for-1st-generic-version-of-abbvies-dry-eye-therapy-restasis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9124302268028259
2/3/2022 11:25:00 PM,Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease,PR Newswire,/news/stocks/viatris-is-first-to-receive-fda-approval-of-generic-restasis-cyclosporine-ophthalmic-emulsion-0-05-to-treat-dry-eye-disease-1031160563,positive,0.8961296677589417
2/4/2022 3:02:35 AM,Viatris Receives FDA Approval For Generic Restasis To Treat Dry Eye Disease ,RTTNews,/news/stocks/viatris-receives-fda-approval-for-generic-restasis-to-treat-dry-eye-disease-1031160693,positive,0.944679856300354
2/4/2022 12:59:00 PM,"Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022",PR Newswire,/news/stocks/viatris-to-host-virtual-investor-event-and-report-fourth-quarter-and-full-year-2021-financial-results-on-february-28-2022-1031162212,neutral,0.9299609661102295
2/25/2022 2:57:51 PM,Notable earnings before Monday's open,Seeking Alpha,https://seekingalpha.com/news/3805966-notable-earnings-before-mondays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8824691772460938
2/25/2022 7:04:24 PM,Will Viatris Q4 results bring earnings surprise?,Seeking Alpha,https://seekingalpha.com/news/3806123-will-viatris-q4-2021-results-bring-earnings-surprise?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.644595205783844
2/27/2022 3:01:13 PM,Viatris is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/viatris-q4-earnings-preview-1031235239,neutral,0.933413565158844
2/27/2022 3:26:47 PM,"The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-27-march-5-earnings-multiple-regulatory-decisions-take-the-spotlight-1031235310,neutral,0.818364143371582
2/27/2022 9:17:58 PM,India's Biocon Biologics agrees to buy Viatris biosimilar assets for up to $3.335B,Seeking Alpha,https://seekingalpha.com/news/3806680-indias-biocon-biologics-agrees-to-buy-viatris-biosimilar-assets-for-up-to-3335b?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5527728796005249
2/28/2022 11:04:43 AM,"Viatris GAAP EPS of -$0.22 misses by $0.45, revenue of $4.33B misses by $10M",Seeking Alpha,https://seekingalpha.com/news/3806724-viatris-gaap-eps-of-0_22-misses-0_45-revenue-of-4_33b-misses-10m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5771796107292175
2/28/2022 11:55:29 AM,"Viatris reports Q4 results, Biocon deal; authorizes $1B stock buyback",Seeking Alpha,https://seekingalpha.com/news/3806749-viatris-stock-rises-amid-q4-results-biocon-deal-authorizes-1b-stock-buyback?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6177189350128174
2/28/2022 12:00:00 PM,Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Fu...,PR Newswire,/news/stocks/viatris-reports-strong-fourth-quarter-and-full-year-2021-financial-results-issues-2022-financial-guidance-completes-comprehensive-strategic-review-unveils-plan-to-reshape-the-company-for-the-fu-1031237448,positive,0.9347793459892273
2/28/2022 12:11:50 PM,Viatris Inc. Q4 Loss Decreases,RTTNews,/news/stocks/viatris-inc-q4-loss-decreases-1031237513,negative,0.9212513566017151
2/28/2022 3:01:23 PM,"IntriCon, NeuroSense top healthcare gainers; Aurinia, Lexicon lead losers' pack",Seeking Alpha,https://seekingalpha.com/news/3806913-intricon-neurosense-top-healthcare-gainers-aurinia-lexicon-lead-losers-pack?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7757875919342041
2/28/2022 3:20:26 PM,"Biocon Biologics To Buy Viatris' Biosimilars Assets For Up To $3.335 Bln In Stock, Cash ",RTTNews,/news/stocks/biocon-biologics-to-buy-viatris-biosimilars-assets-for-up-to-3-335-bln-in-stock-cash-1031238546,neutral,0.8622677326202393
2/28/2022 4:23:32 PM,Viatris sinks to a 52-week low after Q4 earnings and Biocon deal,Seeking Alpha,https://seekingalpha.com/news/3806964-vtrs-stock-sinks-to-a-52-week-low-after-biocon-deal?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9690069556236267
2/28/2022 4:38:08 PM,Mid-Morning Market Update: Markets Open Lower Amid Ongoing Russia-Ukraine Conflict,Benzinga,/news/stocks/mid-morning-market-update-markets-open-lower-amid-ongoing-russia-ukraine-conflict-1031238832,negative,0.9655493497848511
2/28/2022 5:37:18 PM,"EVBG, IRNT and NTRB among mid-day movers",Seeking Alpha,https://seekingalpha.com/news/3807061-evbg-irnt-and-ntrb-among-mid-day-movers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9064186215400696
2/28/2022 6:43:43 PM,42 Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/42-stocks-moving-in-monday-s-mid-day-session-1031239439,negative,0.5072711110115051
3/1/2022 10:40:44 AM,67 Biggest Movers From Yesterday,Benzinga,/news/stocks/67-biggest-movers-from-yesterday-1031241838,neutral,0.6736032962799072
3/1/2022 3:36:56 PM,Viatris draws downgrades on Wall Street after Q4 earnings,Seeking Alpha,https://seekingalpha.com/news/3807749-vtrs-stock-lower-as-outlook-draws-downgrades-on-wall-street?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9367819428443909
3/1/2022 4:04:18 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-1-2022-1031243533,neutral,0.5384483337402344
3/1/2022 10:30:00 PM,Viatris to Participate in Upcoming Investor Conferences,PR Newswire,/news/stocks/viatris-to-participate-in-upcoming-investor-conferences-1031244740,neutral,0.8616368770599365
3/5/2022 5:00:18 PM,Viatris stands out amid selloff in generic drugmakers,Seeking Alpha,https://seekingalpha.com/news/3809915-vtrs-stock-stands-out-amid-selloff-in-generic-drugmakers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8516199588775635
3/9/2022 2:25:52 PM,"AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar",Benzinga,/news/stocks/abbvie-alvotech-resolve-us-patent-dispute-related-to-humira-biosimilar-1031266276,neutral,0.4447286128997803
3/10/2022 12:35:12 PM,7 Drug Stocks to Consider After the Viatris Plunge,InvestorPlace,/news/stocks/7-drug-stocks-to-consider-after-the-viatris-plunge-abbv-bmy-gsk-vtrs-jnj-teva-pfe-nvs-mrk-1031269941,neutral,0.926745593547821
3/10/2022 1:36:46 PM,Viatris price target lowered at Citi following Biocon deal and earnings,Seeking Alpha,https://seekingalpha.com/news/3812107-vtrs--stock-adds-bear-at-citi-after-biocon-deal-and-earnings?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4701792299747467
3/11/2022 4:41:42 PM,Amphastar climbs after Q4 beat as Piper Sandler raises target to a Street high,Seeking Alpha,https://seekingalpha.com/news/3812788-amphastar-climbs-after-q4-beat-as-piper-sandler-raises-target?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7673787474632263
3/15/2022 8:18:47 PM,Viatris wins FDA approval for first generic of AstraZeneca’s Symbicort,Seeking Alpha,https://seekingalpha.com/news/3813823-viatris-wins-fda-approval-for-generic-of-astrazenecas-symbicort?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8522506952285767
3/16/2022 7:29:24 AM,"FDA Approves First Generic Of Symbicort To Treat Asthma, COPD ",RTTNews,/news/stocks/fda-approves-first-generic-of-symbicort-to-treat-asthma-copd-1031283809,positive,0.8343161344528198
3/16/2022 12:30:00 PM,"Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partner...",PR Newswire,/news/stocks/viatris-inc-announces-receipt-of-the-first-fda-approval-for-generic-version-of-symbicort-inhalation-aerosol-breyna-budesonide-and-formoterol-fumarate-dihydrate-inhalation-aerosol-in-partner-1031284630,positive,0.8822259306907654
3/16/2022 5:26:37 PM,"Viatris CEO, director buy shares worth ~$520K",Seeking Alpha,https://seekingalpha.com/news/3814231-viatris-ceo-director-buy-shares-worth-520k?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8890156745910645
3/17/2022 7:22:50 PM,Viatris wins Tecfidera patent battle as court denies Biogen’s petition,Seeking Alpha,https://seekingalpha.com/news/3814713-viatris-wins-tecfidera-patent-battle-as-court-denies-biogens-petition?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5104275941848755
3/17/2022 7:54:00 PM,Viatris Defeats Biogen's Attempt to Revive Tecfidera Patent,PR Newswire,/news/stocks/viatris-defeats-biogen-s-attempt-to-revive-tecfidera-patent-1031289807,neutral,0.6128709316253662
3/18/2022 3:00:20 AM,Viatris Says Defeats Biogen's Attempt To Revive Tecfidera Patent ,RTTNews,/news/stocks/viatris-says-defeats-biogen-s-attempt-to-revive-tecfidera-patent-1031290263,neutral,0.3871126174926758
3/22/2022 2:06:30 PM,7 Cheap Stocks to Buy Now if You Have $100 to Spend,InvestorPlace,/news/stocks/7-cheap-stocks-to-buy-now-if-you-have-100-to-spend-1031298735,neutral,0.9245370030403137
3/30/2022 3:00:00 PM,Sesame Workshop and Viatris Launch New Emotional Health and Wellbeing Resources for Families Grappling with Effects of COVID-19,PR Newswire,/news/stocks/sesame-workshop-and-viatris-launch-new-emotional-health-and-wellbeing-resources-for-families-grappling-with-effects-of-covid-19-1031319052,positive,0.6451531648635864
4/3/2022 11:32:49 PM,"The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-3-april-9-bioxcel-fda-decision-neurology-conference-presentations-take-the-spotlight-1031328267,neutral,0.9425358772277832
4/8/2022 12:59:00 PM,"Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022",PR Newswire,/news/stocks/viatris-inc-to-release-first-quarter-2022-financial-results-on-may-9-2022-1031342629,neutral,0.9382122159004211
4/11/2022 11:48:55 AM,Goldman screens companies with best and worst pricing power into earnings season,Seeking Alpha,https://seekingalpha.com/news/3822185-godlman-screens-companies-with-best-and-worst-pricing-power-into-earnings-season?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9079514741897583
4/12/2022 7:25:18 PM,Cantor lists pharma stocks with notable changes in short interest,Seeking Alpha,https://seekingalpha.com/news/3822816-vtrs-stock-among-pharma-stocks-with-notable-decline-in-short-interest?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.925432026386261
4/13/2022 11:36:10 AM,Biogen’s Aduhelm Crashes the Biotech Sector,InvestorPlace,/news/stocks/biib-stock-biogen-aduhelm-crashes-the-biotech-sector-1031353098,neutral,0.6810705065727234
4/13/2022 2:15:54 PM,"The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More",Benzinga,/news/stocks/the-daily-biotech-pulse-glaxosmithkline-and-halozyme-go-shopping-mylan-s-insulin-glargine-recall-turning-point-shares-lung-cancer-data-and-more-1031353335,neutral,0.9408669471740723
4/14/2022 4:19:44 PM,Viatris recalls insulin batch due to potential missing label,Seeking Alpha,https://seekingalpha.com/news/3823524-viatris-recalls-insulin-batch-due-to-potential-missing-label?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9564436078071594
4/22/2022 12:00:43 AM,Pfizer: What Comes After the Covid-19 Fire?,InvestorPlace,/news/stocks/pfe-stock-what-comes-after-the-covid-fire-1031373557,neutral,0.8588873744010925
5/3/2022 10:34:01 AM,Goldman highlights top sector picks for high dividend growth and yield,Seeking Alpha,https://seekingalpha.com/news/3830044-goldman-highlights-sector-picks-for-high-dividend-growth-and-yield?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.786922812461853
5/6/2022 1:56:43 PM,Notable earnings before Monday's open,Seeking Alpha,https://seekingalpha.com/news/3834310-notable-earnings-before-mondays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8824691772460938
5/6/2022 2:29:03 PM,Will Viatris Q1 results bring earnings surprise,Seeking Alpha,https://seekingalpha.com/news/3834322-will-viatris-q1-results-bring-earnings-surprise?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5594643950462341
5/6/2022 9:38:21 PM,"Viatris files for mixed shelf offering, size not disclosed",Seeking Alpha,https://seekingalpha.com/news/3834686-viatris-files-for-mixed-shelf-offering-size-not-disclosed?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.944278359413147
5/8/2022 3:01:13 PM,Viatris is about to announce its earnings — here's what to expect,Markets Insider Automation,/news/stocks/viatris-stock-q1-earnings-preview-1031433380,neutral,0.9400046467781067
5/9/2022 11:02:11 AM,"Viatris GAAP EPS of $0.33 beats by $0.25, revenue of $4.19B misses by $70M",Seeking Alpha,https://seekingalpha.com/news/3834835-viatris-gaap-eps-of-0_33-beats-0_25-revenue-of-4_19b-misses-70m?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5123684406280518
5/9/2022 12:59:00 PM,Viatris Reports Strong First-Quarter 2022 Results,PR Newswire,/news/stocks/viatris-reports-strong-first-quarter-2022-results-1031435984,positive,0.9494697451591492
5/9/2022 1:14:27 PM,Viatris Inc. Q1 Earnings Summary,RTTNews,/news/stocks/viatris-inc-q1-earnings-summary-1031436086,neutral,0.7869659662246704
5/9/2022 1:25:01 PM,"Viatris Maintains FY22 Revenue Outlook, Declares Dividend - Update ",RTTNews,/news/stocks/viatris-maintains-fy22-revenue-outlook-declares-dividend-update-1031436139,neutral,0.9158641695976257
5/9/2022 2:02:46 PM,"Better Therapeutics, Great Elm top healthcare gainers; TherapeuticsMD, Sutro Biopharma lead losers' pack",Seeking Alpha,https://seekingalpha.com/news/3835002-better-therapeutics-great-elm-top-healthcare-gainers-therapeuticsmd-sutro-biopharma-lead-losers-pack?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8818463087081909
5/9/2022 2:13:05 PM,Viatris gains despite 1Q revenue miss as cashflow tops estimates,Seeking Alpha,https://seekingalpha.com/news/3834910-vtrs-stock-lower-as-1q-revenue-miss-forecasts?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7976800799369812
5/9/2022 7:26:47 PM,27 Recession-Resistant Stocks To Look At Now,Benzinga,/news/stocks/27-recession-resistant-stocks-to-look-at-now-1031437901,neutral,0.7209761738777161
5/10/2022 1:57:07 PM,Viatris downgrades to underweight at Piper Sandler on business repositioning,Seeking Alpha,https://seekingalpha.com/news/3835959-viatris-downgrades-to-underweight-at-piper-sandler-on-business-repositioning?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8799397349357605
5/10/2022 3:13:52 PM,Expert Ratings for Viatris,Benzinga,/news/stocks/expert-ratings-for-viatris-1031442437,neutral,0.8434876799583435
5/10/2022 4:17:40 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-10-2022-1031442728,neutral,0.5236536264419556
5/16/2022 12:59:00 PM,"Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals",PR Newswire,/news/stocks/viatris-publishes-sustainability-report-highlighting-2021-progress-achievements-and-goals-1031463915,neutral,0.8031265139579773
5/17/2022 1:28:30 PM,Teva raised to Neutral at BofA citing a near-term opioid deal,Seeking Alpha,https://seekingalpha.com/news/3839977-teva-stock-raised-to-neutral-at-bofa-citing-a-near-term-opioid-deal?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9449172616004944
5/20/2022 3:22:56 PM,These 20 stocks saw the biggest plunges during earnings season,Seeking Alpha,https://seekingalpha.com/news/3841384-these-20-stocks-were-saw-the-biggest-plunges-during-earnings-season?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9676730632781982
5/20/2022 11:30:00 PM,Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference,PR Newswire,/news/stocks/viatris-to-participate-in-goldman-sachs-43rd-annual-global-healthcare-conference-1031479605,neutral,0.7620708346366882
6/7/2022 1:27:49 PM,7 High-Quality Dividend Stocks With High Yields,InvestorPlace,/news/stocks/7-high-quality-dividend-stocks-with-high-yields-wba-fl-1031513707,neutral,0.5746045112609863
6/14/2022 12:16:58 PM,Viatris initiated Sell at UBS on biosimilar exit,Seeking Alpha,https://seekingalpha.com/news/3848370-vtrs-stock-in-focus-as-ubs-initiates-sell-on-biosimilar-exist?utm_source=businessinsider&utm_medium=referral,neutral,0.9249760508537292
6/14/2022 4:03:40 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-14-2022-1031528265,neutral,0.5047081112861633
7/1/2022 12:59:00 PM,"Viatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022",PR Newswire,/news/stocks/viatris-inc-to-release-second-quarter-2022-financial-results-on-august-8-2022-1031562783,neutral,0.9354320764541626
7/7/2022 6:46:56 AM,Mylan Pharma Recalls Unbranded Insulin Glargine Injection Pens ,RTTNews,/news/stocks/mylan-pharma-recalls-unbranded-insulin-glargine-injection-pens-1031571952,neutral,0.7118825316429138
7/22/2022 7:16:39 PM,Viatris extends decline to reach 52-week low,Seeking Alpha,https://seekingalpha.com/news/3859763-vtrs-stock-extends-decline-to-reach-52-week-low?utm_source=businessinsider&utm_medium=referral,negative,0.9566466808319092
8/4/2022 2:30:04 PM,Organon tightens 2022 revenue guidance on forex headwinds,Seeking Alpha,https://seekingalpha.com/news/3867321-organon-tightens-2022-revenue-guidance-on-forex-headwinds?utm_source=businessinsider&utm_medium=referral,negative,0.9247259497642517
8/5/2022 2:14:37 PM,Notable earnings before Monday's open,Seeking Alpha,https://seekingalpha.com/news/3868225-notable-earnings-before-mondays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8824691772460938
8/5/2022 4:29:00 PM,Viatris Q2 2022 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3868294-viatris-q2-2022-earnings-preview?utm_source=businessinsider&utm_medium=referral,neutral,0.9202198386192322
8/7/2022 3:01:13 PM,Here's what to expect from Viatris's earnings report,Markets Insider Automation,/news/stocks/viatris-stock-q2-earnings-preview-1031657749,neutral,0.9278970956802368
8/8/2022 11:03:33 AM,"Viatris GAAP EPS of $0.26 beats by $0.07, revenue of $4.12B misses by $60M, lowers FY22 revenue guidance",Seeking Alpha,https://seekingalpha.com/news/3868646-viatris-gaap-eps-of-0_26-beats-0_07-revenue-of-4_12b-misses-60m?utm_source=businessinsider&utm_medium=referral,negative,0.8534895181655884
8/8/2022 11:38:25 AM,Viatris declares $0.12 dividend,Seeking Alpha,https://seekingalpha.com/news/3868642-viatris-inc-declares-0_12-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.8892531991004944
8/8/2022 11:49:41 AM,Viatris lowers 2022 guidance to reflect currency impact,Seeking Alpha,https://seekingalpha.com/news/3868691-vtrrs-stock-higher-even-as-company-lowers-2022-guidance?utm_source=businessinsider&utm_medium=referral,negative,0.6762751936912537
8/8/2022 12:59:00 PM,Viatris Reports Strong Second Quarter 2022 Results,PR Newswire,/news/stocks/viatris-reports-strong-second-quarter-2022-results-1031660683,positive,0.9483988881111145
8/8/2022 1:14:15 PM,Viatris Inc. Q2 Earnings Summary,RTTNews,/news/stocks/viatris-inc-q2-earnings-summary-1031660769,neutral,0.7297752499580383
8/8/2022 1:25:50 PM,"Viatris Trims FY22 Revenue Outlook, Declares Dividend - Update ",RTTNews,/news/stocks/viatris-trims-fy22-revenue-outlook-declares-dividend-update-1031660809,negative,0.9145117998123169
8/11/2022 1:40:26 PM,Regeneron IPR hearing suggests Eylea patent may be in trouble - analyst,Seeking Alpha,https://seekingalpha.com/news/3871614-regeneron-ipr-hearing-suggests-eylea-patent-may-be-in-trouble-analyst?utm_source=businessinsider&utm_medium=referral,negative,0.9611251354217529
9/2/2022 10:00:00 PM,"Micron, Intel among new ideas in BofA's Alpha Surprise screen",Seeking Alpha,https://seekingalpha.com/news/3879926-micron-intel-among-new-ideas-in-bofas-alpha-surprise-screen?utm_source=businessinsider&utm_medium=referral,neutral,0.7787503004074097
9/4/2022 4:00:35 PM,Cannabis legalization wiped off ~$10B market cap in pharma sector – study,Seeking Alpha,https://seekingalpha.com/news/3880198-cannabis-legalization-wiped-off-10b-market-cap-in-pharma-sector?utm_source=businessinsider&utm_medium=referral,negative,0.9227800965309143
9/6/2022 12:59:00 PM,Viatris Inc. to Participate in BofA Global Research Global Healthcare Conference,PR Newswire,/news/stocks/viatris-inc-to-participate-in-bofa-global-research-global-healthcare-conference-1031725693,neutral,0.6388940811157227
9/13/2022 10:30:24 AM,7 Screaming Buy Stock Picks to Beat the September Market Slump,InvestorPlace,/news/stocks/7-screaming-buy-stock-picks-to-beat-the-september-market-slump-1031739340,positive,0.8326026797294617
9/21/2022 12:51:42 PM,Viatris partner hits main goal in study for long-acting multiple sclerosis therapy,Seeking Alpha,https://seekingalpha.com/news/3884792-viatris-partner-hits-main-goal-for-long-acting-multiple-sclerosis-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.5586429834365845
9/22/2022 11:45:01 AM,Viatris faces legal setback to market generics for Merck’s diabetic drugs,Seeking Alpha,https://seekingalpha.com/news/3885200-viatris-faces-legal-setback-to-market-generics-for-mercks-diabetic-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.9569201469421387
9/22/2022 1:46:08 PM,U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris ,RTTNews,/news/stocks/u-s-district-court-rules-in-favor-of-merck-in-patent-infringement-suit-against-viatris-1031759015,negative,0.4640287756919861
9/22/2022 7:25:05 PM,Healthcare outperforms S&P 500 as large cap pharma rebounds,Seeking Alpha,https://seekingalpha.com/news/3885399-healthcare-outperforms-sp-500-as-large-cap-pharma-rebounds?utm_source=businessinsider&utm_medium=referral,positive,0.6939451694488525
9/27/2022 12:01:50 PM,Aquestive adds 20% as epinephrine sublingual film outperforms autoinjector,Seeking Alpha,https://seekingalpha.com/news/3886278-aqst-stock-gains-as-epinephrine-sublingual-film-outperforms-autoinjector?utm_source=businessinsider&utm_medium=referral,positive,0.9457864165306091
9/27/2022 5:16:34 PM,EU generic drugmakers flag risks to production due to rising costs,Seeking Alpha,https://seekingalpha.com/news/3886451-eu-generic-drugmakers-flag-risks-to-production-due-to-rising-costs?utm_source=businessinsider&utm_medium=referral,negative,0.9452967643737793
9/29/2022 7:45:38 PM,Merck wins appeals court ruling against Viatris over generic diabetic drugs,Seeking Alpha,https://seekingalpha.com/news/3887242-merck-wins-appeals-court-ruling-against-viatris-over-generic-diabetic-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.7449671626091003
10/3/2022 2:18:57 PM,Biogen bid to revive Tecfidera patents denied by U.S. Supreme Court,Seeking Alpha,https://seekingalpha.com/news/3887968-biogen-bid-to-revive-tecfidera-patents-denied-by-us-supreme-court?utm_source=businessinsider&utm_medium=referral,neutral,0.6359108686447144
10/10/2022 12:20:45 PM,Merck raised to Buy at Guggenheim citing earnings beats ahead,Seeking Alpha,https://seekingalpha.com/news/3889960-merck-raised-to-buy-at-guggenheim-citing-earnings-beats-ahead?utm_source=businessinsider&utm_medium=referral,negative,0.675652801990509
10/11/2022 3:44:08 PM,Viatris stock rises amid potential plans for €3B sale of European OTC assets,Seeking Alpha,https://seekingalpha.com/news/3890398-viatris-stock-rises-amid-potential-plans-for-3b-sale-of-european-otc-assets?utm_source=businessinsider&utm_medium=referral,positive,0.8331267833709717
10/11/2022 8:15:00 PM,Viatris Named to Forbes' Annual List of the World's Best Employers for the Second Year in a Row,PR Newswire,/news/stocks/viatris-named-to-forbes-annual-list-of-the-world-s-best-employers-for-the-second-year-in-a-row-1031797052,positive,0.8598289489746094
10/13/2022 10:13:54 PM,US Supreme Court beats back Novartis request to stop Gilenya generics,Seeking Alpha,https://seekingalpha.com/news/3891270-us-supreme-court-beats-back-novartis-request-to-stop-gilenya-generics?utm_source=businessinsider&utm_medium=referral,negative,0.8351075053215027
10/17/2022 2:34:50 PM,Morgan Stanley says large cap healthcare remains attractive amid macro concerns,Seeking Alpha,https://seekingalpha.com/news/3891861-morgan-stanely-says-large-cap-healthcare-remains-attractive-amid-macro-concerns?utm_source=businessinsider&utm_medium=referral,positive,0.9349676966667175
10/21/2022 4:11:34 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-21-2022-1031824639,neutral,0.504640519618988
10/24/2022 10:30:00 PM,"Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022",PR Newswire,/news/stocks/viatris-to-report-financial-results-for-the-third-quarter-2022-and-provide-an-update-on-its-february-28-investor-event-on-november-7-2022-1031829839,neutral,0.9487837553024292
11/4/2022 2:26:15 PM,Notable earnings before Monday's open,Seeking Alpha,https://seekingalpha.com/news/3901982-notable-earnings-before-mondays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8824691772460938
11/4/2022 6:04:43 PM,Viatris Q3 2022 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3902233-viatris-q3-2022-earnings-preview?utm_source=businessinsider&utm_medium=referral,neutral,0.9195235371589661
11/6/2022 3:01:13 PM,Viatris is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/viatris-q3-earnings-preview-stock-1031878302,neutral,0.9340234994888306
11/6/2022 5:00:24 PM,"Off-patent drugs make up 91% of prescriptions, but only 18% of spending - report",Seeking Alpha,https://seekingalpha.com/news/3902378-off-patent-drugs-make-up-91-of-prescriptions-18-of-spending?utm_source=businessinsider&utm_medium=referral,neutral,0.8645551800727844
11/7/2022 11:53:04 AM,"Viatris GAAP EPS of $0.29 beats by $0.10, revenue of $4.07B misses by $70M",Seeking Alpha,https://seekingalpha.com/news/3902459-viatris-gaap-eps-of-0_29-beats-0_10-revenue-of-4_07b-misses-70m?utm_source=businessinsider&utm_medium=referral,positive,0.49462565779685974
11/7/2022 12:50:00 PM,Viatris Reports Strong Third Quarter 2022 Results,PR Newswire,/news/stocks/viatris-reports-strong-third-quarter-2022-results-1031880796,positive,0.9491209387779236
11/7/2022 1:00:33 PM,Viatris Inc. Profit Climbs In Q3,RTTNews,/news/stocks/viatris-inc-profit-climbs-in-q3-1031880833,positive,0.9234695434570312
11/7/2022 1:05:57 PM,"Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update ",RTTNews,/news/stocks/viatris-reaffirms-fy22-revenue-outlook-declares-dividend-update-1031880904,neutral,0.8165649175643921
11/7/2022 1:40:58 PM,Oyster Point Pharma jumps 37% as Viatris agrees to acquire for $11/share in cash,Seeking Alpha,https://seekingalpha.com/news/3902522-oyst-stock-on-watch-after-buyout-deal-with-viatris?utm_source=businessinsider&utm_medium=referral,positive,0.9117056131362915
11/7/2022 2:00:00 PM,Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event,PR Newswire,/news/stocks/viatris-announces-two-acquisitions-to-create-what-it-expects-to-be-a-leading-ophthalmology-franchise-plans-to-provide-strategic-update-on-its-february-2022-investor-event-1031881127,positive,0.7835937738418579
11/7/2022 2:05:19 PM,"Cramer On This Stock Up 138% Year-To-Date: 'Santa Can't Afford That Coal, It's Going Up Too Much'",Benzinga,/news/stocks/cramer-on-this-stock-up-138-year-to-date-santa-can-t-afford-that-coal-it-s-going-up-too-much-1031881232,positive,0.8951486349105835
11/7/2022 2:23:19 PM,Viatris To Acquire Oyster Point And Famy Life Sciences To Create Ophthalmology Franchise ,RTTNews,/news/stocks/viatris-to-acquire-oyster-point-and-famy-life-sciences-to-create-ophthalmology-franchise-1031881256,neutral,0.9282357692718506
11/7/2022 3:51:18 PM,Viatris (VTRS) Stock Pops 17% on Acquisition News,InvestorPlace,/news/stocks/viatris-vtrs-stock-pops-17-on-acquisition-news-1031882159,positive,0.8518332242965698
11/7/2022 4:13:42 PM,Viatris nears five-month high after Oyster Pharma deal and Q3 earnings,Seeking Alpha,https://seekingalpha.com/news/3902665-vtrs-stock-nears-five-month-high-after-oyster-buyout-and-q3-earnings?utm_source=businessinsider&utm_medium=referral,positive,0.9182357788085938
11/7/2022 4:16:33 PM,IAA Stock Moves as Ritchie Bros Acquires Company in $7.3 Billion Deal,InvestorPlace,/news/stocks/iaa-stock-moves-as-ritchie-bros-acquires-company-in-7-3-billion-deal-1031882360,negative,0.4379589855670929
11/7/2022 5:37:48 PM,Viatris declares $0.12 dividend,Seeking Alpha,https://seekingalpha.com/news/3902802-viatris-declares-012-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.8892531991004944
11/7/2022 5:44:54 PM,"Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge",Benzinga,/news/stocks/viatris-bolsters-its-ophthalmology-franchise-with-oyster-point-pharma-deal-shares-surge-1031882401,positive,0.9511692523956299
11/7/2022 6:46:20 PM,Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/why-oyster-point-pharma-shares-are-trading-higher-by-around-40-here-are-49-stocks-moving-in-monday-s-mid-day-session-1031882576,neutral,0.8721359968185425
11/8/2022 8:00:34 AM,"Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday",Benzinga,/news/stocks/spirit-aerosystems-oyster-point-pharma-snap-and-other-big-gainers-from-monday-1031885274,positive,0.8248158097267151
11/8/2022 11:00:20 AM,Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday,Benzinga,/news/stocks/why-huadi-international-group-shares-dipped-around-91-here-are-79-biggest-movers-from-yesterday-1031885646,negative,0.6602123975753784
11/8/2022 12:31:40 PM,Ocuphire adds 24% as Viatris agrees to sell lead asset,Seeking Alpha,https://seekingalpha.com/news/3903415-ocup-stock-climbs-as-viatris-agrees-to-sell-lead-asset?utm_source=businessinsider&utm_medium=referral,positive,0.5403494834899902
11/8/2022 3:43:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-8-2022-1031887337,neutral,0.48834267258644104
11/9/2022 7:18:25 PM,Regeneron pares gains after PTAB rules agains Eylea patent claims (update),Seeking Alpha,https://seekingalpha.com/news/3904717-ptab-rules-against-regeron-eylea-patent?utm_source=businessinsider&utm_medium=referral,neutral,0.46817755699157715
11/10/2022 2:13:57 PM,4 Analysts Have This to Say About Viatris,Benzinga,/news/stocks/4-analysts-have-this-to-say-about-viatris-1031898513,neutral,0.9157141447067261
11/10/2022 2:30:00 PM,Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent,PR Newswire,/news/stocks/viatris-wins-court-decision-invalidating-astrazeneca-s-symbicort-patent-1031898562,negative,0.9282090067863464
11/10/2022 3:07:30 PM,"Viatris, Kindeva Announce U.S. Court's Invalidation Of AstraZeneca's Symbicort Patent ",RTTNews,/news/stocks/viatris-kindeva-announce-u-s-court-s-invalidation-of-astrazeneca-s-symbicort-patent-1031898918,negative,0.6592246294021606
11/10/2022 3:11:32 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-10-2022-1031898964,negative,0.5016787648200989
11/10/2022 3:35:50 PM,Where Viatris Stands With Analysts,Benzinga,/news/stocks/where-viatris-stands-with-analysts-1031899107,neutral,0.9263688325881958
11/10/2022 5:53:59 PM,Analyst Ratings for Viatris,Benzinga,/news/stocks/analyst-ratings-for-viatris-1031899712,neutral,0.9213034510612488
11/10/2022 5:58:05 PM,Viatris wins court decision on AstraZeneca Symbicort patent,Seeking Alpha,https://seekingalpha.com/news/3905838-viatris-wins-court-decision-on-astrazeneca-symbicort-patent?utm_source=businessinsider&utm_medium=referral,negative,0.4490143954753876
11/10/2022 7:08:56 PM,Expert Ratings for Viatris,Benzinga,/news/stocks/expert-ratings-for-viatris-1031899965,neutral,0.8434876799583435
11/10/2022 11:04:17 PM,"DOJ, SEC charge Viatris executive with insider trading; co says he is on leave of absence",Seeking Alpha,https://seekingalpha.com/news/3906188-doj-sec-charge-viatris-executive-with-insider-trading-co-says-he-is-on-leave-of-absence?utm_source=businessinsider&utm_medium=referral,negative,0.6933053731918335
11/14/2022 2:01:17 PM,Teva slips as JPMorgan downgrades on growth concerns,Seeking Alpha,https://seekingalpha.com/news/3907087-teva-stock-slips-as-jpmorgan-downgrades-on-growth-concerns?utm_source=businessinsider&utm_medium=referral,negative,0.9490519165992737
11/18/2022 12:59:00 PM,Viatris Named U.S. In-House Legal Team of the Year for Intellectual Property Litigation by LMG Life Sciences,PR Newswire,/news/stocks/viatris-named-u-s-in-house-legal-team-of-the-year-for-intellectual-property-litigation-by-lmg-life-sciences-1031924913,positive,0.858426570892334
11/29/2022 2:00:00 PM,Viatris Completes Biosimilars Transaction with Biocon Biologics,PR Newswire,/news/stocks/viatris-completes-biosimilars-transaction-with-biocon-biologics-1031941957,positive,0.5163446664810181
12/13/2022 9:04:01 AM,Shield Therapeutics To Work With Viatris To Bring Accrufer In The U.S. ,RTTNews,/news/stocks/shield-therapeutics-to-work-with-viatris-to-bring-accrufer-in-the-u-s-1031968288,positive,0.7488808035850525
12/13/2022 9:23:16 AM,Calliditas To Work With Viatris To Bring Nefecon To Japanese Patients ,RTTNews,/news/stocks/calliditas-to-work-with-viatris-to-bring-nefecon-to-japanese-patients-1031968321,neutral,0.6155003905296326
12/13/2022 11:55:03 AM,"Calliditas, Viatris sign license deal for kidney disease drug Nefecon in Japan",Seeking Alpha,https://seekingalpha.com/news/3916428-calliditas-viatris-sign-license-deal-for-kidney-disease-drug-nefecon-in-japan?utm_source=businessinsider&utm_medium=referral,positive,0.8858449459075928
12/14/2022 3:00:00 PM,Viatris Announces Approval of Emissions Reduction Targets by the Science Based Target initiative (SBTi),PR Newswire,/news/stocks/viatris-announces-approval-of-emissions-reduction-targets-by-the-science-based-target-initiative-sbti-1031971826,positive,0.6775242686271667
12/14/2022 3:05:00 PM,"Viatris Announces Donations Totaling $1 Million to Provide Aid Supporting Access to Healthcare, Food Security and Water Stewardship",PR Newswire,/news/stocks/viatris-announces-donations-totaling-1-million-to-provide-aid-supporting-access-to-healthcare-food-security-and-water-stewardship-1031971877,positive,0.9071653485298157
12/14/2022 4:51:43 PM,Fresenius Kabi becomes latest drugmaker to win approval of biosimilar of AbbVie's Humira,Seeking Alpha,https://seekingalpha.com/news/3916989-fresenius-kabi-becomes-latest-drugmaker-to-win-approval-of-biosimilar-of-abbvie-humira?utm_source=businessinsider&utm_medium=referral,positive,0.8937796354293823
12/18/2022 2:04:41 PM,The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond,InvestorPlace,/news/stocks/the-7-hottest-healthcare-stocks-to-own-for-2023-and-beyond-1031978729,neutral,0.8950048089027405
12/21/2022 6:04:26 PM,The 7 Best Crypto and Stocks to Buy as Christmas Gifts This Year,InvestorPlace,/news/stocks/the-7-best-crypto-and-stocks-to-buy-as-christmas-gifts-this-year-1031985594,neutral,0.8753215074539185
12/23/2022 12:59:00 PM,Viatris Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/viatris-inc-to-participate-in-41st-annual-j-p-morgan-healthcare-conference-1031988704,neutral,0.8175584673881531
12/28/2022 11:11:30 PM,"'Sell The Darlings, Own The Dogs': Why It May Soon Be Time To Buy Tesla, Meta And Other Worst-Performing Stocks Of 2022",Benzinga,/news/stocks/sell-the-darlings-own-the-dogs-why-it-may-soon-be-time-to-buy-tesla-meta-and-other-worst-performing-stocks-of-2022-1031992852,neutral,0.9072889089584351
12/29/2022 10:05:00 PM,Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors,PR Newswire,/news/stocks/viatris-announces-appointments-of-scott-a-smith-and-elisha-w-finney-to-the-company-s-board-of-directors-1031994133,neutral,0.9026259779930115
12/30/2022 12:28:33 PM,7 Cheap Large-Cap Stocks to Buy Before They Surge Higher,InvestorPlace,/news/stocks/cheap-large-cap-stocks-1031607723,neutral,0.8062047362327576
1/2/2023 12:22:52 PM,Why These 7 Healthcare Stocks Could Soar in 2023,InvestorPlace,/news/stocks/why-these-7-healthcare-stocks-could-soar-in-2023-1031996442,neutral,0.8209434747695923
1/3/2023 3:00:00 PM,"Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division",PR Newswire,/news/stocks/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1031997853,neutral,0.9157670140266418
1/3/2023 3:30:27 PM,"Viatris closes Oyster Point, Famy acquisitions to establish eye care division",Seeking Alpha,https://seekingalpha.com/news/3921591-viatris-closes-oyster-point-famy-acquisitions-to-establish-eye-care-division?utm_source=businessinsider&utm_medium=referral,neutral,0.9096803069114685
1/6/2023 6:30:04 PM,"Catalyst watch: ICR Conference, JPMorgan Healthcare Conference, CPI, major bank reports",Seeking Alpha,https://seekingalpha.com/news/3922727-catalyst-watch-icr-conference-jpmorgan-healthcare-conference-cpi-major-banks-report?utm_source=businessinsider&utm_medium=referral,neutral,0.9261020421981812
1/10/2023 6:45:11 PM,Cosmos extends and updates deal to acquire Cana Laboratories,Seeking Alpha,https://seekingalpha.com/news/3923434-cosmos-extends-and-updates-deal-to-acquire-cana-laboratories?utm_source=businessinsider&utm_medium=referral,neutral,0.5548141598701477
1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral,positive,0.8150349855422974
1/27/2023 11:39:37 AM,Viatris' Farxiga generic gets EMA committee's backing for approval in EU,Seeking Alpha,https://seekingalpha.com/news/3928859-viatris-farxiga-generic-gets-ema-committees-backing-for-approval-in-eu?utm_source=businessinsider&utm_medium=referral,positive,0.8997344970703125
1/27/2023 4:00:43 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-27-2023-1032046978,negative,0.55882728099823
1/27/2023 6:00:26 PM,Where Viatris Stands With Analysts,Benzinga,/news/stocks/where-viatris-stands-with-analysts-1032047290,neutral,0.9263688325881958
1/29/2023 5:00:25 PM,AbbVie’s global bestseller to face knockoffs starting this week,Seeking Alpha,https://seekingalpha.com/news/3929211-abbvies-global-bestseller-to-face-knockoffs-starting-this-week?utm_source=businessinsider&utm_medium=referral,negative,0.4311627745628357
2/9/2023 6:26:00 PM,"Advent, CVC among bidders for Viatris European consumer-health assets - report",Seeking Alpha,https://seekingalpha.com/news/3934398-advent-cvc-among-bidders-for-viatris-european-consume-health-assets-report?utm_source=businessinsider&utm_medium=referral,neutral,0.677600085735321
2/13/2023 11:40:05 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), IQVIA Holdings (IQV) and Viatris (VTRS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-iqvia-holdings-iqv-and-viatris-vtrs-1032090836,neutral,0.9209754467010498
2/13/2023 1:53:56 PM,Ocuphire rises as eye therapy goes under FDA review,Seeking Alpha,https://seekingalpha.com/news/3935172-ocup-stock-rises-eye-therapy-goes-under-fda-review?utm_source=businessinsider&utm_medium=referral,positive,0.7486730813980103
2/14/2023 11:49:39 AM,Viatris hit with FDA snub for cancer biosimilar,Seeking Alpha,https://seekingalpha.com/news/3935620-viatris-hit-with-fda-snub-for-cancer-biosimilar?utm_source=businessinsider&utm_medium=referral,negative,0.8592739701271057
2/15/2023 5:15:00 PM,"Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023",PR Newswire,/news/stocks/viatris-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023-1032099650,neutral,0.9406962394714355
2/15/2023 6:14:32 PM,Medicare mulls limiting per month costs for generic drugs at $2,Seeking Alpha,https://seekingalpha.com/news/3936542-medicare-mulls-limiting-per-month-costs-for-generic-drugs-at-2?utm_source=businessinsider&utm_medium=referral,neutral,0.4218192398548126
2/17/2023 8:55:07 AM,Viatris (VTRS) Gets a Hold from BMO Capital,TipRanks,/news/stocks/viatris-vtrs-gets-a-hold-from-bmo-capital-1032105313,neutral,0.9075927138328552
2/17/2023 12:54:30 PM,Viatris downgraded at BMO on unclear growth trajectory,Seeking Alpha,https://seekingalpha.com/news/3937632-vtrs-stock-downgraded-bmo-unclear-growth-trajectory?utm_source=businessinsider&utm_medium=referral,negative,0.9326798915863037
2/17/2023 2:30:25 PM,NVIDIA To Rally Around Over 30%? Here Are 10 Other Analyst Forecasts For Friday,Benzinga,/news/stocks/nvidia-to-rally-around-over-30-here-are-10-other-analyst-forecasts-for-friday-1032106072,neutral,0.9212729930877686
2/17/2023 4:01:36 PM,"Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-february-17-2023-1032106369,negative,0.5371188521385193
2/17/2023 7:56:48 PM,BMO Downgrades Viatris As Its Looks For More Visibility On Next Phase,Benzinga,/news/stocks/bmo-downgrades-viatris-as-its-looks-for-more-visibility-on-next-phase-1032106872,negative,0.9258395433425903
2/19/2023 5:00:10 PM,The next big wave of patent cliffs is ahead; expect biopharma M&A to rise – report,Seeking Alpha,https://seekingalpha.com/news/3937885-next-big-wave-of-patent-cliffs-ahead-biopharma-m-and-a-to-rise?utm_source=businessinsider&utm_medium=referral,positive,0.9136704802513123
2/24/2023 12:10:52 PM,"Analysts Are Bullish on Top Healthcare Stocks: Viatris (VTRS), NuVasive (NUVA)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-viatris-vtrs-nuvasive-nuva-1032123300,positive,0.6456423997879028
2/24/2023 5:55:44 PM,"Earnings week ahead: Salesforce, Target, Broadcom, Lowe’s, and more",Seeking Alpha,https://seekingalpha.com/news/3940754-earnings-week-ahead-salesforce-target-broadcom-lowes-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.917677640914917
2/24/2023 7:58:23 PM,Revenue decline expected once again for Viatris' Q4 earnings,Seeking Alpha,https://seekingalpha.com/news/3940843-revenue-decline-expected-once-again-for-viatris-q4-earnings?utm_source=businessinsider&utm_medium=referral,negative,0.9755964875221252
2/26/2023 3:01:13 PM,Viatris earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/viatris-q4-quarterly-earnings-preview-1032125416,neutral,0.9303571581840515
2/27/2023 11:05:57 AM,"Viatris GAAP EPS of $0.83 beats by $0.68, revenue of $3.87B misses by $120M",Seeking Alpha,https://seekingalpha.com/news/3941017-viatris-gaap-eps-of-083-beats-by-068-revenue-of-387b-misses-by-120m?utm_source=businessinsider&utm_medium=referral,positive,0.4906313121318817
2/27/2023 12:00:00 PM,Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance,PR Newswire,/news/stocks/viatris-reports-strong-fourth-quarter-and-full-year-2022-financial-results-and-provides-2023-financial-guidance-1032127171,positive,0.9475260376930237
2/27/2023 12:05:10 PM,Viatris Inc. Q4 Earnings Summary,RTTNews,/news/stocks/viatris-inc-q4-earnings-summary-1032127179,neutral,0.7848691940307617
2/27/2023 12:09:50 PM,Viatris swings to $1B net earnings in Q4 thanks to biosimilar sale,Seeking Alpha,https://seekingalpha.com/news/3941047-viatris-swings-to-1b-net-earnings-in-q4-thanks-to-biosimilar-sale?utm_source=businessinsider&utm_medium=referral,positive,0.5603638291358948
2/27/2023 12:29:12 PM,"Viatris Sees Weak Revenues, Adj. EBITDA In FY23 - Update ",RTTNews,/news/stocks/viatris-sees-weak-revenues-adj-ebitda-in-fy23-update-1032127255,negative,0.9690700769424438
2/27/2023 12:47:06 PM,"Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk",Benzinga,/news/stocks/nasdaq-s-p-500-futures-rebound-in-new-trading-week-but-rising-bond-yields-remain-a-risk-1032127322,negative,0.49223172664642334
2/27/2023 12:55:26 PM,"Viatris appoints Scott A. Smith to succeed CEO Michael Goettler, effective April 1",Seeking Alpha,https://seekingalpha.com/news/3941072-viatris-appoints-scott-a-smith-to-succeed-ceo-michael-goettler-effective-april-1?utm_source=businessinsider&utm_medium=referral,neutral,0.8815039992332458
2/27/2023 1:45:00 PM,"Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023",PR Newswire,/news/stocks/viatris-announces-appointment-of-scott-a-smith-as-ceo-effective-april-1-2023-1032127515,neutral,0.911013126373291
2/27/2023 1:59:34 PM,"Viatris Names Scott Smith CEO, Succeeding Michael Goettler, With Effect From April 1 ",RTTNews,/news/stocks/viatris-names-scott-smith-ceo-succeeding-michael-goettler-with-effect-from-april-1-1032127548,neutral,0.9212273955345154
2/27/2023 4:18:22 PM,VTRS Stock Alert: What to Know as Viatris Appoints New CEO,InvestorPlace,/news/stocks/vtrs-stock-alert-what-to-know-as-viatris-appoints-new-ceo-1032128350,neutral,0.9312487840652466
2/27/2023 4:42:52 PM,Is Warren Buffett Going to Buy Tesla (TSLA) Stock?,InvestorPlace,/news/stocks/is-warren-buffett-going-to-buy-tesla-tsla-stock-1032128439,neutral,0.9382798075675964
2/27/2023 5:01:56 PM,Why Is Intuitive Machines (LUNR) Stock Up Today?,InvestorPlace,/news/stocks/why-is-intuitive-machines-lunr-stock-up-today-1032128509,neutral,0.7496805787086487
2/28/2023 12:20:08 PM,"Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Viatris (VTRS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biomarin-pharmaceutical-bmrn-eli-lilly-co-lly-and-viatris-vtrs-1032131149,neutral,0.9082995653152466
2/28/2023 5:01:01 PM,4 Analysts Have This to Say About Viatris,Benzinga,/news/stocks/4-analysts-have-this-to-say-about-viatris-1032132303,neutral,0.9157141447067261
3/3/2023 12:20:56 PM,Viatris joins AbbVie and Lilly in protesting against U.K. drug pricing deal,Seeking Alpha,https://seekingalpha.com/news/3943792-viatris-joins-abbvie-and-lilly-in-protesting-against-uk-drug-pricing-deal?utm_source=businessinsider&utm_medium=referral,negative,0.7959650754928589
3/7/2023 4:05:11 PM,Viatris goes ex-dividend tomorrow,Seeking Alpha,https://seekingalpha.com/news/3944949-viatris-declares-012-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.5938276648521423
3/12/2023 2:00:00 PM,Biosimilars expected to save $180B over next five years as more gain approval,Seeking Alpha,https://seekingalpha.com/news/3946583-biosimilars-expected-to-save-180b-over-next-five-years-as-more-gain-approval?utm_source=businessinsider&utm_medium=referral,positive,0.8129683136940002
3/14/2023 6:17:36 PM,Senate bill to streamline generic drug approval reintroduced,Seeking Alpha,https://seekingalpha.com/news/3947357-senate-bill-to-streamline-generic-drug-approval-reintroduced?utm_source=businessinsider&utm_medium=referral,neutral,0.714120090007782
3/20/2023 9:02:23 PM,"Merck, Viatris settle patent dispute over Januvia",Seeking Alpha,https://seekingalpha.com/news/3949220-merck-viatris-settle-patent-dispute-over-januvia?utm_source=businessinsider&utm_medium=referral,neutral,0.6210030317306519
3/23/2023 6:33:09 PM,White House seeking alternative supply chains for pharmaceutical ingredients,Seeking Alpha,https://seekingalpha.com/news/3950575-white-house-alternative-supply-chains-pharmaceutical-ingredients-drug-shortages?utm_source=businessinsider&utm_medium=referral,neutral,0.6495422124862671
3/30/2023 9:13:16 AM,"Viatris, Aurobindo, Cipla to make generics of ViiV's HIV drug for low income countries",Seeking Alpha,https://seekingalpha.com/news/3952570-viatris-aurobindo-cipla-to-make-generics-of-viiv-hiv-drug?utm_source=businessinsider&utm_medium=referral,neutral,0.7398712038993835
3/31/2023 3:11:44 PM,Viatris pulls generic HIV drug filing in EU on bioequivalence woes,Seeking Alpha,https://seekingalpha.com/news/3953222-viatris-pulls-generic-hiv-drug-filing-in-eu-bioequivalence-woes?utm_source=businessinsider&utm_medium=referral,negative,0.9556043148040771
3/31/2023 8:09:59 PM,Viatris asks for new bids for OTC business after initial offers disappoint - report,Seeking Alpha,https://seekingalpha.com/news/3953313-viatris-asks-for-new-bids-for-otc-business-after-initial-offers-disappoint-report?utm_source=businessinsider&utm_medium=referral,positive,0.4864040017127991
3/31/2023 9:46:00 PM,Viatris Wins Summary Judgment in New York Securities Class Action,PR Newswire,/news/stocks/viatris-wins-summary-judgment-in-new-york-securities-class-action-1032208147,negative,0.5561076998710632
4/4/2023 11:15:53 AM,The 7 Most Undervalued Nasdaq Stocks to Buy in April 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-nasdaq-stocks-to-buy-in-april-2023-1032213342,neutral,0.7264565825462341
4/6/2023 1:00:00 PM,NCD Academy Launches New Health Equity and Social Determinants of Health Course,PR Newswire,/news/stocks/ncd-academy-launches-new-health-equity-and-social-determinants-of-health-course-1032218731,neutral,0.6825564503669739
4/12/2023 3:00:00 PM,"Viatris to Report First Quarter 2023 Financial Results on May 8, 2023",PR Newswire,/news/stocks/viatris-to-report-first-quarter-2023-financial-results-on-may-8-2023-1032227385,neutral,0.9363591074943542
4/17/2023 2:48:07 PM,Supreme Court turns down Sanofi bid to revive EpiPen lawsuit against Viatris,Seeking Alpha,https://seekingalpha.com/news/3956965-sanofi-stock-bid-revive-epipen-lawsuit-against-viatris-fails?utm_source=businessinsider&utm_medium=referral,negative,0.5614740252494812
4/23/2023 4:00:00 PM,What is behind biotech M&A resurgence?,Seeking Alpha,https://seekingalpha.com/news/3958874-reasons-for-biotech-buyout-resurgence?utm_source=businessinsider&utm_medium=referral,neutral,0.9020150899887085
4/24/2023 1:00:00 PM,Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting,PR Newswire,/news/stocks/viatris-and-mapi-pharma-to-highlight-latest-results-of-multiple-sclerosis-research-at-american-academy-of-neurology-75th-annual-meeting-1032253645,neutral,0.9273462295532227
4/24/2023 4:02:00 PM,Analyst Expectations for Viatris's Future,Benzinga,/news/stocks/analyst-expectations-for-viatris-s-future-1032254556,positive,0.8642430305480957
4/24/2023 5:00:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-24-2023-1032254745,neutral,0.49273809790611267
4/25/2023 3:38:42 PM,Bipartisan agreement reached in Senate prescription drug price legislation,Seeking Alpha,https://seekingalpha.com/news/3959793-bipartisan-agreement-reached-senate-prescription-drug-price-legislation?utm_source=businessinsider&utm_medium=referral,positive,0.8105085492134094
4/25/2023 5:00:39 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-25-2023-1032259110,neutral,0.5121983289718628
5/5/2023 3:24:04 PM,Viatris Q1 earnings in focus amid plans to divest some European assets,Seeking Alpha,https://seekingalpha.com/news/3966558-viatris-q1-earnings-in-focus-amid-plans-to-divest-european-assets?utm_source=businessinsider&utm_medium=referral,negative,0.5560412406921387
5/5/2023 3:40:34 PM,Notable earnings before Monday's open,Seeking Alpha,https://seekingalpha.com/news/3966571-notable-earnings-before-mondays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8824691772460938
5/5/2023 6:00:36 PM,"Earnings Week Ahead: Fox Corporation, Disney, Airbnb, and more",Seeking Alpha,https://seekingalpha.com/news/3966576-earnings-week-ahead-fox-corporation-disney-airbnb-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9131557941436768
5/8/2023 7:17:14 AM,Notable earnings before Monday's open,Seeking Alpha,https://seekingalpha.com/news/3966831-notable-earnings-before-mondays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8824691772460938
5/8/2023 11:41:02 AM,Viatris expects return to growth as Q1 topline contracts 11%,Seeking Alpha,https://seekingalpha.com/news/3966948-viatris-expects-return-growth-q1-topline-contracts?utm_source=businessinsider&utm_medium=referral,positive,0.9525508880615234
5/8/2023 11:47:09 AM,Viatris reports Q1 results,Seeking Alpha,https://seekingalpha.com/news/3966952-viatris-reports-q1-results?utm_source=businessinsider&utm_medium=referral,neutral,0.8943977952003479
5/8/2023 12:59:00 PM,Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1],PR Newswire,/news/stocks/viatris-reports-strong-financial-and-operational-results-for-first-quarter-2023-and-reaffirms-full-year-2023-guidance-ranges-1-1032301595,positive,0.8774306178092957
5/8/2023 1:08:31 PM,Viatris Inc. Q1 Income Falls,RTTNews,/news/stocks/viatris-inc-q1-income-falls-1032301636,neutral,0.670532763004303
5/8/2023 1:32:49 PM,"Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend - Update ",RTTNews,/news/stocks/viatris-reaffirms-fy23-revenue-outlook-declares-dividend-update-1032301706,neutral,0.8090972900390625
5/9/2023 3:25:07 AM,Goldman Sachs Sticks to Their Hold Rating for Viatris (VTRS),TipRanks,/news/stocks/goldman-sachs-sticks-to-their-hold-rating-for-viatris-vtrs-1032304065,neutral,0.9002745747566223
5/9/2023 11:45:20 AM,Viatris (VTRS) Receives a Hold from Piper Sandler,TipRanks,/news/stocks/viatris-vtrs-receives-a-hold-from-piper-sandler-1032306389,neutral,0.7572205662727356
5/16/2023 3:00:00 PM,Viatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine,PR Newswire,/news/stocks/viatris-publishes-sustainability-report-showcasing-2022-progress-on-building-sustainable-access-to-medicine-1032331364,positive,0.5078111886978149
5/17/2023 12:59:00 PM,Viatris to Participate in Goldman Sachs 44th Annual Global Healthcare Conference,PR Newswire,/news/stocks/viatris-to-participate-in-goldman-sachs-44th-annual-global-healthcare-conference-1032334434,neutral,0.7643042802810669
5/18/2023 11:45:46 AM,7 Stocks That Are Long Overdue for a Relief Rally,InvestorPlace,/news/stocks/7-stocks-that-are-long-overdue-for-a-relief-rally-1032337277,negative,0.44167134165763855
5/18/2023 9:29:00 PM,"ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS",PR Newswire,/news/stocks/rosen-trusted-national-trial-counsel-encourages-viatris-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-vtrs-1032338380,neutral,0.8249101042747498
5/22/2023 12:30:00 PM,Viatris Announces Appointment of Leo Groothuis to Company's Board of Directors,PR Newswire,/news/stocks/viatris-announces-appointment-of-leo-groothuis-to-company-s-board-of-directors-1032342180,neutral,0.9358534812927246
5/22/2023 1:40:00 PM,Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year,PR Newswire,/news/stocks/robert-j-coury-to-transition-from-executive-chairman-of-viatris-to-chairman-emeritus-and-senior-strategic-advisor-to-the-board-and-management-at-the-end-of-the-year-1032342350,neutral,0.9391269683837891
5/22/2023 4:01:10 PM,Viatris goes ex dividend tomorrow,Seeking Alpha,https://seekingalpha.com/news/3973838-viatris-inc-declares-missing-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.6347002983093262
5/23/2023 9:40:05 AM,"Analysts Conflicted on These Healthcare Names: Zoetis (ZTS), Viatris (VTRS) and Blueprint Medicines (BPMC)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-zoetis-zts-viatris-vtrs-and-blueprint-medicines-bpmc-1032344662,negative,0.5457767248153687
5/25/2023 1:40:00 AM,"ROSEN, A RESPECTED AND LEADING FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS",PR Newswire,/news/stocks/rosen-a-respected-and-leading-firm-encourages-viatris-inc-investors-with-losses-to-secure-counsel-before-important-deadline-in-securities-class-action-vtrs-1032349920,neutral,0.748406708240509
5/30/2023 3:00:00 PM,Viatris Named to USA Today's Inaugural List of America's Climate Leaders 2023,PR Newswire,/news/stocks/viatris-named-to-usa-today-s-inaugural-list-of-america-s-climate-leaders-2023-1032358334,neutral,0.8507377505302429
6/1/2023 5:11:00 AM,VTRS INVESTOR NEWS: TOP RANKED ROSEN LAW FIRM Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS,PR Newswire,/news/stocks/vtrs-investor-news-top-ranked-rosen-law-firm-encourages-viatris-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-vtrs-1032362806,positive,0.5431165099143982
6/8/2023 3:24:00 AM,"ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS",PR Newswire,/news/stocks/rosen-skilled-investor-counsel-encourages-viatris-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-vtrs-1032377152,neutral,0.8206577897071838
6/14/2023 4:00:00 AM,"ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS",PR Newswire,/news/stocks/rosen-leading-investor-counsel-encourages-viatris-inc-investors-with-losses-to-secure-counsel-before-important-deadline-in-securities-class-action-vtrs-1032387499,neutral,0.8425876498222351
6/20/2023 11:45:00 PM,"ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS",PR Newswire,/news/stocks/rosen-a-leading-investor-rights-law-firm-encourages-viatris-inc-investors-with-losses-to-secure-counsel-before-important-deadline-in-securities-class-action-vtrs-1032400368,neutral,0.8494036793708801
6/23/2023 1:50:46 PM,Viatris cut to Underweight at Barclays citing a “show-me” story,Seeking Alpha,https://seekingalpha.com/news/3982397-viatris-stock-downgraded-barclays-citing-show-me-story?utm_source=businessinsider&utm_medium=referral,negative,0.9507773518562317
6/23/2023 5:01:45 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-23-2023-1032407188,neutral,0.4926295876502991
6/26/2023 3:08:45 PM,Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/check-out-3-health-care-stocks-with-over-4-dividend-yields-from-wall-street-s-most-accurate-analysts-1032409783,neutral,0.7893310785293579
6/28/2023 11:00:45 AM,Fresh Blood: 3 Stocks Ready to Rally Under New CEOs,InvestorPlace,/news/stocks/3-stocks-ready-to-rally-under-new-ceos-1032414676,positive,0.6786441802978516
6/28/2023 5:45:00 PM,"Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023",PR Newswire,/news/stocks/viatris-to-report-second-quarter-2023-financial-results-on-august-7-2023-1032415726,neutral,0.9333999156951904
6/29/2023 9:02:34 AM,Goldman adds 39 new stocks to its Sharpe Ratio basket with megacaps absent,Seeking Alpha,https://seekingalpha.com/news/3983745-goldman-adds-39-new-stocks-to-its-sharpe-ratio-basket?utm_source=businessinsider&utm_medium=referral,neutral,0.5409156084060669
7/1/2023 1:30:00 AM,"ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS",PR Newswire,/news/stocks/rosen-a-leading-and-longstanding-firm-encourages-viatris-inc-investors-to-secure-counsel-before-important-july-14-deadline-in-securities-class-action-vtrs-1032421730,positive,0.6148775815963745
7/7/2023 2:10:01 PM,3 Stocks to Snag for Less Than Book Value,InvestorPlace,/news/stocks/3-stocks-to-snag-for-less-than-book-value-1032432341,negative,0.6860368847846985
7/7/2023 8:45:00 PM,"ROSEN, NATIONAL TRIAL LAWYERS, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS",PR Newswire,/news/stocks/rosen-national-trial-lawyers-encourages-viatris-inc-investors-to-secure-counsel-before-important-july-14-deadline-in-securities-class-action-vtrs-1032432844,neutral,0.6898663640022278
7/31/2023 12:27:49 PM,Viatris launches first generic of AstraZeneca asthma drug Symbicort,Seeking Alpha,https://seekingalpha.com/news/3993370-viatris-launches-generic-astrazeneca-asthma-drug-symbicort?utm_source=businessinsider&utm_medium=referral,neutral,0.7017961740493774
7/31/2023 12:59:00 PM,"Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstr...",PR Newswire,/news/stocks/viatris-announces-launch-of-breyna-budesonide-and-formoterol-fumarate-dihydrate-inhalation-aerosol-the-first-fda-approved-generic-version-of-symbicort-for-people-with-asthma-and-chronic-obstr-1032494867,positive,0.7982999086380005
8/4/2023 8:06:19 AM,Barclays Remains a Sell on Viatris (VTRS),TipRanks,/news/stocks/barclays-remains-a-sell-on-viatris-vtrs-1032516978,neutral,0.935204029083252
8/4/2023 2:23:15 PM,Notable earnings before Monday's open,Seeking Alpha,https://seekingalpha.com/news/3997581-notable-earnings-before-mondays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8824691772460938
8/4/2023 6:13:24 PM,Viatris hopes for Q2 earnings beats amid negative YTD return,Seeking Alpha,https://seekingalpha.com/news/3997742-viatris-hopes-q2-earnings-beats-negative-ytd-return?utm_source=businessinsider&utm_medium=referral,positive,0.9091459512710571
8/6/2023 3:01:13 PM,Viatris earnings: here's what to expect,Markets Insider Automation,/news/stocks/viatris-stock-price-quarter-earnings-preview-q2-1032520198,neutral,0.9357114434242249
8/7/2023 11:04:57 AM,Viatris beats Q2 top and bottom line estimates; reaffirms FY23 outlook,Seeking Alpha,https://seekingalpha.com/news/3998043-viatris-beats-q2-top-and-bottom-line-estimates-reaffirms-fy23-outlook?utm_source=businessinsider&utm_medium=referral,positive,0.7874992489814758
8/7/2023 11:43:11 AM,Viatris posts first topline beat in over a year as Q2 revenue improves,Seeking Alpha,https://seekingalpha.com/news/3998067-viatris-posts-first-topline-beat-over-year-q2?utm_source=businessinsider&utm_medium=referral,positive,0.9367648363113403
8/7/2023 12:07:17 PM,Viatris multiple sclerosis therapy accepted for FDA review,Seeking Alpha,https://seekingalpha.com/news/3998077-viatris-multiple-sclerosis-therapy-accepted-for-fda-review?utm_source=businessinsider&utm_medium=referral,positive,0.5016387701034546
8/7/2023 12:54:00 PM,Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis,PR Newswire,/news/stocks/viatris-and-mapi-pharma-announce-fda-acceptance-of-new-drug-application-filing-for-ga-depot-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis-1032523392,positive,0.817459762096405
8/7/2023 1:05:13 PM,Viatris Inc. Q2 Profit Drops,RTTNews,/news/stocks/viatris-inc-q2-profit-drops-1032523430,negative,0.9276297688484192
8/7/2023 1:15:05 PM,"Viatris, Mapi Pharma: FDA Accepts For Review NDA For GA Depot To Treat RMS ",RTTNews,/news/stocks/viatris-mapi-pharma-fda-accepts-for-review-nda-for-ga-depot-to-treat-rms-1032523454,neutral,0.674155056476593
8/7/2023 1:25:53 PM,"Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend - Update ",RTTNews,/news/stocks/viatris-reaffirms-fy23-revenue-outlook-declares-dividend-update-1032523513,neutral,0.8090972900390625
8/7/2023 4:19:09 PM,"Elanco Animal Health, Sovos Brands, Veritiv, Graham And Other Big Stocks Moving Higher On Monday",Benzinga,/news/stocks/elanco-animal-health-sovos-brands-veritiv-graham-and-other-big-stocks-moving-higher-on-monday-1032524748,positive,0.919826328754425
8/8/2023 1:15:23 AM,Bank of America Securities Sticks to Its Hold Rating for Viatris (VTRS),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-its-hold-rating-for-viatris-vtrs-1032525820,neutral,0.8981804251670837
8/8/2023 7:16:22 AM,Viatris (VTRS) Receives a Sell from Barclays,TipRanks,/news/stocks/viatris-vtrs-receives-a-sell-from-barclays-1032527396,neutral,0.6470100283622742
8/8/2023 11:40:57 AM,Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Viatris (VTRS),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-astria-therapeutics-atxs-and-viatris-vtrs-1032528484,neutral,0.9077408313751221
8/8/2023 12:55:57 PM,Piper Sandler Sticks to Their Hold Rating for Viatris (VTRS),TipRanks,/news/stocks/piper-sandler-sticks-to-their-hold-rating-for-viatris-vtrs-1032528832,neutral,0.8610387444496155
8/10/2023 4:47:43 PM,S&P changes outlook on Viatris to negative,Seeking Alpha,https://seekingalpha.com/news/4001184-sp-changes-outlook-viatris-negative?utm_source=businessinsider&utm_medium=referral,negative,0.7886262536048889
8/21/2023 12:20:11 PM,"Analysts Are Bullish on These Healthcare Stocks: Supernus Pharmaceuticals (SUPN), Viatris (VTRS)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-supernus-pharmaceuticals-supn-viatris-vtrs-1032569601,positive,0.5470502972602844
8/23/2023 5:35:09 PM,Viatris goes ex-dividend today,Seeking Alpha,https://seekingalpha.com/news/4005656-viatris-inc-declares-missing-dividend?utm_source=businessinsider&utm_medium=referral,negative,0.7354565262794495
8/24/2023 6:12:04 PM,Generic drug prices have dropped significantly since 2006 - report,Seeking Alpha,https://seekingalpha.com/news/4006106-generic-drug-prices-dropped-significantly-since-2006?utm_source=businessinsider&utm_medium=referral,negative,0.9721062183380127
9/5/2023 10:42:18 AM,Viatris wins tentative FDA approval for HIV therapy in children,Seeking Alpha,https://seekingalpha.com/news/4008963-viatris-nabs-tentative-fda-nod-pediatric-hiv-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.9250267744064331
9/5/2023 11:00:00 AM,"Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV",PR Newswire,/news/stocks/viatris-announces-u-s-fda-tentative-approval-of-a-paediatric-formulation-of-abacavir-abc-dolutegravir-dtg-lamivudine-3tc-a-once-daily-treatment-for-children-living-with-hiv-1032604407,positive,0.9121378660202026
9/5/2023 11:26:12 AM,Viatris: FDA Issues Tentative Approval For Single Tablet Regimen In HIV Treatment For Children ,RTTNews,/news/stocks/viatris-fda-issues-tentative-approval-for-single-tablet-regimen-in-hiv-treatment-for-children-1032604468,positive,0.8796321153640747
9/6/2023 5:16:14 PM,Viatris in talks to sell European OTC assets to CVC unit - report,Seeking Alpha,https://seekingalpha.com/news/4009583-viatris-in-talks-to-selll-european-otc-assets-to-cvc-unit-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8923160433769226
9/12/2023 8:45:00 PM,Viatris Named to TIME's World's Best Companies 2023 List,PR Newswire,/news/stocks/viatris-named-to-time-s-world-s-best-companies-2023-list-1032624674,neutral,0.6452662944793701
9/22/2023 4:46:19 PM,'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase,Benzinga,/news/stocks/stocks-in-monopolistic-bull-market-wall-street-analyst-contemplates-a-bright-future-for-next-phase-1032650182,positive,0.7921591997146606
9/27/2023 2:00:00 PM,Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Ago...,PR Newswire,/news/stocks/viatris-and-ocuphire-pharma-announce-fda-approval-of-ryzumvl-phentolamine-ophthalmic-solution-0-75-eye-drops-for-the-treatment-of-pharmacologically-induced-mydriasis-produced-by-adrenergic-ago-1032659094,positive,0.9255364537239075
9/27/2023 2:20:00 PM,"Viatris, Ocuphire Pharma Announce FDA Approval Of RYZUMVl - Quick Facts ",RTTNews,/news/stocks/viatris-ocuphire-pharma-announce-fda-approval-of-ryzumvl-quick-facts-1032659197,positive,0.5865670442581177
9/27/2023 3:04:09 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields-1032659408,neutral,0.8461886048316956
10/1/2023 11:00:00 PM,Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA,PR Newswire,/news/stocks/viatris-announces-agreements-on-remaining-planned-divestitures-upon-closing-would-achieve-its-original-total-target-of-a-multiple-above-12x-on-2022-estimated-adjusted-ebitda-1032668488,positive,0.9047947525978088
10/2/2023 12:21:05 PM,"Analysts Offer Insights on Healthcare Companies: Icosavax (ICVX), Viatris (VTRS) and MoonLake Immunotherapeutics (MLTX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-icosavax-icvx-viatris-vtrs-and-moonlake-immunotherapeutics-mltx-1032670164,neutral,0.8977055549621582
10/3/2023 4:11:21 PM,"'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories",Benzinga,/news/stocks/airbnb-has-foundational-cracks-disney+-follows-netflix-on-subscription-sharing-crackdown-microsoft-s-nadella-criticizes-google-s-exclusive-content-deals-today-s-top-stories-1032675117,negative,0.9165230989456177
10/4/2023 10:56:25 AM,Piper Sandler Sticks to Its Hold Rating for Viatris (VTRS),TipRanks,/news/stocks/piper-sandler-sticks-to-its-hold-rating-for-viatris-vtrs-1032677328,neutral,0.8117388486862183
10/10/2023 3:29:00 PM,"Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023",PR Newswire,/news/stocks/viatris-to-release-third-quarter-2023-financial-results-on-november-7-2023-1032692553,neutral,0.9336146712303162
10/18/2023 2:00:00 PM,Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking,PR Newswire,/news/stocks/viatris-named-to-3bl-s-100-best-corporate-citizens-of-2023-ranking-1032716548,neutral,0.6025080680847168
10/20/2023 11:00:00 PM,"Rajiv Malik to Retire as President of Viatris Effective April 1, 2024",PR Newswire,/news/stocks/rajiv-malik-to-retire-as-president-of-viatris-effective-april-1-2024-1032725252,neutral,0.9065030813217163
10/21/2023 3:19:56 AM,Viatris President Rajiv Malik To Retire In April 2024 ,RTTNews,/news/stocks/viatris-president-rajiv-malik-to-retire-in-april-2024-1032725505,neutral,0.8896900415420532
10/23/2023 3:00:00 PM,Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row,PR Newswire,/news/stocks/viatris-named-to-forbes-annual-list-of-the-world-s-best-employers-for-the-third-year-in-a-row-1032728854,positive,0.8342840075492859
10/30/2023 2:00:00 PM,Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance,PR Newswire,/news/stocks/viatris-to-host-webinar-the-power-of-partnership-to-address-antimicrobial-resistance-1032754009,neutral,0.6809626817703247
11/7/2023 6:07:06 PM,3 Large-Cap Stocks to Buy Trading Below Book Value,InvestorPlace,/news/stocks/3-large-cap-stocks-to-buy-trading-below-book-value-1032789327,neutral,0.9167946577072144
11/7/2023 10:44:55 PM,Viatris Inc. Profit Declines In Q3,RTTNews,/news/stocks/viatris-inc-profit-declines-in-q3-1032789856,negative,0.9694440364837646
11/8/2023 11:01:27 AM,"Analysts Conflicted on These Healthcare Names: Viatris (VTRS), Globus Medical (GMED) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-viatris-vtrs-globus-medical-gmed-and-gilead-sciences-gild-1032796908,negative,0.7037227749824524
11/13/2023 2:00:00 PM,Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD),PR Newswire,/news/stocks/viatris-and-theravance-biopharma-announce-positive-top-line-results-from-yupelri-revefenacin-phase-iii-trial-in-china-for-the-treatment-of-chronic-obstructive-pulmonary-disease-copd-1032812772,positive,0.9451116919517517
11/13/2023 2:49:27 PM,"Viatris, Theravance Report Positive Top-line Results From Phase III Trial For YUPELRI In China ",RTTNews,/news/stocks/viatris-theravance-report-positive-top-line-results-from-phase-iii-trial-for-yupelri-in-china-1032813017,positive,0.9560134410858154
11/14/2023 2:00:00 PM,Viatris to Participate in the Jefferies London Healthcare Conference,PR Newswire,/news/stocks/viatris-to-participate-in-the-jefferies-london-healthcare-conference-1032817550,neutral,0.8218153715133667
11/20/2023 11:30:00 AM,7 Low P/E Stocks Poised to Rebound,InvestorPlace,/news/stocks/7-low-p-e-value-stocks-poised-to-rebound-1032835111,negative,0.7017073035240173
11/30/2023 12:30:00 PM,Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024,InvestorPlace,/news/stocks/buy-alert-analysts-say-these-3-growth-stocks-could-double-in-2024-1032862167,positive,0.9322671890258789
12/15/2023 10:05:00 PM,Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders,PR Newswire,/news/stocks/viatris-shareholders-re-elect-all-nominated-directors-and-approve-all-voting-matters-at-annual-meeting-of-shareholders-1032906029,neutral,0.9468396306037903
12/15/2023 10:45:00 PM,"Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora ""Doretta"" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe M...",PR Newswire,/news/stocks/viatris-continues-its-preparations-for-phase-2-of-its-strategic-plan-by-announcing-the-appointment-of-theodora-doretta-mistras-as-chief-financial-officer-effective-march-1-2024-and-philippe-m-1032906104,neutral,0.934939980506897
12/21/2023 10:05:00 PM,Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/viatris-to-participate-in-42nd-annual-j-p-morgan-healthcare-conference-1032920590,neutral,0.7141304612159729
12/27/2023 1:42:09 PM,3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/3-minutes-to-boost-your-earnings-3-stocks-with-over-3-dividend-yields-in-health-care-sector-from-wall-street-s-most-accurate-analysts-1032927772,positive,0.8053922653198242
1/3/2024 4:26:53 PM,Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth,Benzinga,/news/etf/tech-sell-off-triggers-market-reset-value-stocks-reach-7-month-high-versus-growth-1032940596,positive,0.8445466160774231
1/5/2024 4:36:55 PM,Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today?,Benzinga,/news/stocks/why-is-lung-disease-focused-theravance-biopharma-stock-trading-lower-today-1032946531,negative,0.7374764084815979
1/12/2024 2:26:27 PM,Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/beat-inflation-with-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-street-s-most-accurate-analysts-1032963710,positive,0.9167076349258423
1/12/2024 4:18:11 PM,Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish,Benzinga,/news/stocks/regeneron-pharma-s-pipeline-makes-this-analyst-turn-bullish-1032964340,positive,0.5331723093986511
1/22/2024 4:22:04 PM,"Alight, Viatris gain after Greenlight discloses position in Q4 letter",Seeking Alpha,https://seekingalpha.com/news/4056927-alight-viatris-gain-after-greenlight-discloses-position-in-q4-letter?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.853919506072998
2/14/2024 10:43:34 PM,"Greenlight Capital buys Alight, exits Southwestern Energy",Seeking Alpha,https://seekingalpha.com/news/4067260-greenlight-capital-buys-alight-exits-southwestern-energy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8809266090393066
2/14/2024 11:00:17 PM,"Larry Robbins' Glenview Capital takes in Marvell, cuts stake in Intel and exits Microsoft",Seeking Alpha,https://seekingalpha.com/news/4067280-larry-robbins-glenview-capital-takes-in-marvell-cuts-stake-in-intel-and-exits-microsoft?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6619254350662231
2/20/2024 9:54:57 PM,Viatris stock logs seven straight sessions of gains,Seeking Alpha,https://seekingalpha.com/news/4069113-viatris-stock-set-for-seven-straight-sessions-of-gains?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5862739086151123
2/25/2024 1:00:00 PM,"Earnings week ahead: Salesforce, Plug Power, Zoom, Snowflake, AMC Entertainment and more",Seeking Alpha,https://seekingalpha.com/news/4071132-earnings-week-ahead-salesforce-plug-power-zoom-video-snowflake-amc-entertainment-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9263616800308228
2/26/2024 9:27:37 PM,3 Bargain Stocks to Snatch Up Before They Bounce Back,InvestorPlace,/news/stocks/3-bargain-stocks-to-snatch-up-before-they-bounce-back-1033104519,neutral,0.8430182337760925
2/27/2024 3:01:13 PM,Viatris is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/viatris-stock-q4-earnings-preview-1033107485,neutral,0.9340234994888306
2/27/2024 6:56:00 PM,Viatris Q4 2023 earnings preview: Margins remain under pressure,Seeking Alpha,https://seekingalpha.com/news/4072505-viatris-q4-2023-earnings-preview-no-surprises-ahead-as-margins-remain-under-pressure?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9255252480506897
2/27/2024 8:19:52 PM,3 Overextended Stocks That Need to Slash Their Dividends ASAP,InvestorPlace,/news/stocks/3-overextended-stocks-that-need-to-slash-their-dividends-asap-1033109211,negative,0.9424558281898499
2/28/2024 7:20:35 AM,"Viatris, Idorsia Announce Global Research And Development Collaboration ",RTTNews,/news/stocks/viatris-idorsia-announce-global-research-and-development-collaboration-1033110954,neutral,0.753559410572052
2/28/2024 9:52:49 AM,Biotech Stocks Facing FDA Decision In March 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2024-1033111344,neutral,0.9174318909645081
2/28/2024 11:16:01 AM,Viatris secures right to late-stage drug assets in Idorsia pact,Seeking Alpha,https://seekingalpha.com/news/4072864-viatris-secures-right-for-two-late-stage-drug-assets-in-idorsia-pact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8072302341461182
2/28/2024 11:34:38 AM,"Viatris EPS of -$0.64, revenue of $3.83B misses by $50M",Seeking Alpha,https://seekingalpha.com/news/4072871-viatris-eps-of-064-revenue-of-383b-misses-by-50m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7806415557861328
2/28/2024 12:26:36 PM,"Viatris in charts: Net sales in Emerging markets rise 6.6% Y/Y, Brands up over 4% in Q4",Seeking Alpha,https://seekingalpha.com/news/4072922-viatris-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9537574052810669
2/28/2024 12:38:46 PM,Viatris Inc. Q4 Earnings Summary,RTTNews,/news/stocks/viatris-inc-q4-earnings-summary-1033112043,neutral,0.7848691940307617
2/28/2024 12:47:11 PM,Viatris sets 2024 guidance above consensus; boosts share buybacks,Seeking Alpha,https://seekingalpha.com/news/4072952-viatris-tops-estimates-2024-outlook-boosts-share-buybacks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9370340704917908
2/28/2024 1:15:01 PM,Viatris Guides FY24 In Line With Estimates - Update ,RTTNews,/news/stocks/viatris-guides-fy24-in-line-with-estimates-update-1033112215,neutral,0.7490585446357727
2/28/2024 5:41:22 PM,Dividend rally: Top 10 large-cap performers in 2024 with at least a 3% yield,Seeking Alpha,https://seekingalpha.com/news/4073191-top-10-ytd-stocks-with-at-least-a-3-dividend-yield?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9276929497718811
2/28/2024 8:08:13 PM,"Stocks Fall Ahead Of Fed's Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What's Driving Markets Wednesday?",Benzinga,/news/stocks/stocks-fall-ahead-of-fed-s-inflation-data-unitedhealth-sinks-bitcoin-tops-61-000-what-s-driving-markets-wednesday-1033114622,negative,0.8233840465545654
2/29/2024 10:46:24 AM,Viatris Sell Rating Maintained Amid EBITDA Concerns and Uncertain Growth Prospects,TipRanks,/news/stocks/viatris-sell-rating-maintained-amid-ebitda-concerns-and-uncertain-growth-prospects-1033118232,negative,0.941794216632843
2/29/2024 11:32:59 AM,Barclays Sticks to Their Sell Rating for Viatris (VTRS),TipRanks,/news/stocks/barclays-sticks-to-their-sell-rating-for-viatris-vtrs-1033118557,neutral,0.86136794090271
3/4/2024 7:55:35 AM,Barclays Remains a Sell on Viatris (VTRS),TipRanks,/news/stocks/barclays-remains-a-sell-on-viatris-vtrs-1033127733,neutral,0.935204029083252
3/8/2024 3:21:57 PM,Teva upgraded at J.P. Morgan on upcoming catalysts,Seeking Alpha,https://seekingalpha.com/news/4077679-teva-stock-upgraded-jp-morgan-catalysts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8432720303535461
3/11/2024 1:43:30 PM,FDA rejects Viatris/Mapi long-acting version of Teva's Copaxone,Seeking Alpha,https://seekingalpha.com/news/4077985-fda-rejects-viatris-mapi-long-acting-version-of-tevas-copaxone?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.4834405481815338
3/14/2024 5:43:27 PM,Russell 1000 stocks with secured dividends that are not stretched - BofA,Seeking Alpha,https://seekingalpha.com/news/4079614-secure-not-stretched-dividends-stocks-of-the-russell-1000-quintile-2-bofa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.899575412273407
3/27/2024 8:00:58 AM,Australian Stocks: CSL Shares Retain “Strong Buy” Rating from Analysts,TipRanks,/news/stocks/australian-stocks-csl-shares-retain-strong-buy-rating-from-analysts-1033200565,positive,0.9491696953773499
3/28/2024 9:31:54 AM,Analysts Conflicted on These Healthcare Names: Alphatec Holdings (ATEC) and Viatris (VTRS),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-alphatec-holdings-atec-and-viatris-vtrs-1033205145,negative,0.7154080867767334
4/1/2024 1:24:01 PM,Viatris Announces US Commercial Launch Of RYZUMVl 0.75% ,RTTNews,/news/stocks/viatris-announces-us-commercial-launch-of-ryzumvl-0-75-1033210686,neutral,0.6995870471000671
4/1/2024 1:48:01 PM,Ocuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner Viatris ,RTTNews,/news/stocks/ocuphire-announces-commercial-launch-of-ryzumvi-in-u-s-by-its-partner-viatris-1033210725,neutral,0.7920994758605957
4/1/2024 4:17:16 PM,Teva and Viatris revives chance to dispute J&J's schizophrenia drug patent,Seeking Alpha,https://seekingalpha.com/news/4085739-teva-and-viatris-revives-chance-to-dispute-jjs-schizophrenia-drug-patent?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6067003011703491
4/3/2024 12:00:00 PM,Steady Returns Ahead: 3 Dividend Stocks for Stable Income in Q2,InvestorPlace,/news/stocks/steady-returns-ahead-3-dividend-stocks-for-stable-income-in-q2-1033218678,positive,0.8438929319381714
4/4/2024 12:55:15 PM,Viatris- Theramex deal for women's care products raises antitrust concerns in U.K.,Seeking Alpha,https://seekingalpha.com/news/4087219-viatris-deal-raises-uk-antitrust-concerns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9332636594772339
4/13/2024 2:52:04 PM,AbbVie keeps Humira market share near 100% despite biosimilars: report,Seeking Alpha,https://seekingalpha.com/news/4089412-abbvie-retains-humira-market-despite-copycats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5874672532081604
4/15/2024 1:14:00 PM,Viatris Announces Launch Of Bioequivalent Generic For Copaxone In Canada - Quick Facts ,RTTNews,/news/stocks/viatris-announces-launch-of-bioequivalent-generic-for-copaxone-in-canada-quick-facts-1033248758,positive,0.5293984413146973
4/15/2024 6:19:53 PM,BTIG Research Predicts Over 118% Rally for These 3 Stocks,InvestorPlace,/news/stocks/btig-research-predicts-over-118-rally-for-these-3-stocks-1033250641,positive,0.8785549402236938
4/17/2024 1:26:31 PM,CVS favors Humira copycats hurting AbbVie’s market share: Evercore,Seeking Alpha,https://seekingalpha.com/news/4090466-cvs-favors-humira-copycats-hurting-abbvies-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8803040981292725
5/4/2024 8:47:00 PM,16 out of 24 health care companies beat topline numbers this week- Earnings scorecard,Seeking Alpha,https://seekingalpha.com/news/4099757-16-out-of-24-health-care-companies-beat-topline-numbers-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8876544833183289
5/5/2024 12:00:00 PM,"Earnings week ahead: Disney, Palantir, Shopify, Uber, Plug Power and more",Seeking Alpha,https://seekingalpha.com/news/4099576-earnings-week-ahead-disney-palantir-realty-income-shopify-uber-plug-power-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9203616976737976
5/8/2024 3:01:13 PM,Viatris is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/viatris-quarter-earnings-preview-q1-1033347307,neutral,0.933413565158844
5/8/2024 5:03:54 PM,Viatris Q1 Earnings Preview: Focus remains on capital allocation,Seeking Alpha,https://seekingalpha.com/news/4102745-viatris-q1-earnings-preview-focus-remains-on-capital-allocation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7862836122512817
5/9/2024 11:00:57 AM,"Viatris Non-GAAP EPS of $0.67 in-line, revenue of $3.66B misses by $30M",Seeking Alpha,https://seekingalpha.com/news/4103481-viatris-non-gaap-eps-of-0_67-in-line-revenue-of-3_66b-misses-30m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6665470004081726
5/9/2024 11:24:05 AM,"Earnings Summary: Viatris reports mixed Q1 results, reaffirms FY2024 outlook",Seeking Alpha,https://seekingalpha.com/news/4103526-earnings-summary-viatris-reports-mixed-q1-results-reaffirms-fy2024-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9655206799507141
5/9/2024 11:37:00 AM,Viatris in charts: Net sales drop Y/Y across all markets in Q1,Seeking Alpha,https://seekingalpha.com/news/4103554-viatris-in-charts-net-sales-drop-yy-across-all-markets-in-q1?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9741834402084351
5/9/2024 1:07:12 PM,"Viatris Inc. Q1 Profit Drops, Inline With Estimates ",RTTNews,/news/stocks/viatris-inc-q1-profit-drops-inline-with-estimates-1033355309,negative,0.9731751084327698
5/9/2024 3:56:09 PM,"VTRS Stock Earnings: Viatris Meets EPS, Misses Revenue for Q1 2024",InvestorPlace,/news/stocks/vtrs-stock-earnings-viatris-for-q1-of-2024-1033357628,neutral,0.8475172519683838
5/9/2024 6:16:44 PM,Viatris declares $0.12 dividend,Seeking Alpha,https://seekingalpha.com/news/4103957-viatris-declares-012-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8892531991004944
5/9/2024 6:42:35 PM,"Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?",Benzinga,/news/etf/stocks-rebound-as-rising-jobless-claims-sustain-rate-cut-hopes-dollar-falls-gold-rallies-what-s-driving-markets-thursday-1033357731,negative,0.8095728158950806
5/10/2024 10:05:01 AM,"Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Bluebird Bio (BLUE) and Viatris (VTRS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-health-catalyst-hcat-bluebird-bio-blue-and-viatris-vtrs-1033363002,neutral,0.9043567776679993
5/12/2024 3:22:00 PM,8 out of 12 S&P 500 healthcare companies beat profit consensus this week: Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4104780-8-out-of-12-sp-500-healthcare-companies-beat-profit-consensus-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7937322854995728
5/16/2024 3:01:24 PM,"Larry Robbins' Glenview Capital takes in Broadcom, exits Intel among Q1 moves",Seeking Alpha,https://seekingalpha.com/news/4107499-larry-robbins-glenview-capital-takes-in-broadcom-exits-intel-among-q1-moves?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9156339764595032
5/17/2024 6:08:34 PM,Regeneron wins temporary restraining order preventing Eylea generic launch (update),Seeking Alpha,https://seekingalpha.com/news/4107951-regeneron-wins-temporary-restraining-order-preventing-eylea-generics?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6379203200340271
6/11/2024 7:08:20 PM,Regeneron wins injunction blocking Mylan from launching generic version of its eye drug Eylea (update),Seeking Alpha,https://seekingalpha.com/news/4114936-regeneron-wins-permanent-injunction-blocking-generic-version-of-its-eye-drug-eylea?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5751960873603821
6/14/2024 4:44:17 PM,Regeneron wins injunction blocking Samsung Bioepis from launching generic Eylea,Seeking Alpha,https://seekingalpha.com/news/4116326-regeneron-wins-injunction-blocking-samsung-bioepis-from-launching-generic-eylea?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9033765196800232
6/26/2024 6:39:53 PM,European Commission Approves Proposed Acquisition Of Viatris By Cooper Consumer Health ,RTTNews,/news/stocks/european-commission-approves-proposed-acquisition-of-viatris-by-cooper-consumer-health-1033508742,neutral,0.839394211769104
7/2/2024 12:07:59 PM,Viatris’ Mylan no longer subject of DOJ drug price-fixing probe,Seeking Alpha,https://seekingalpha.com/news/4121557-viatris-mylan-no-longer-subject-of-doj-antitrust-probe-on-drug-price-fixing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8706696629524231
7/2/2024 1:41:37 PM,Viatris: Mylan No Longer Subject Of Generic Drug Industry Antitrust Investigation ,RTTNews,/news/stocks/viatris-mylan-no-longer-subject-of-generic-drug-industry-antitrust-investigation-1033522593,neutral,0.8435221314430237
7/10/2024 1:17:28 PM,Bank of America Securities Sticks to Its Sell Rating for Viatris (VTRS),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-its-sell-rating-for-viatris-vtrs-1033544358,neutral,0.8842869997024536
7/12/2024 4:35:09 PM,"U.S. Senate passes bill to trim Big Pharma ""patent thickets""",Seeking Alpha,https://seekingalpha.com/news/4123999-us-senate-passes-bill-to-cut-trim-big-pharma-patent-thickets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5233776569366455
7/17/2024 6:09:20 PM,Big pharma rally after J&J earnings,Seeking Alpha,https://seekingalpha.com/news/4125149-big-pharma-rally-after-jj-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5109472870826721
7/19/2024 12:06:51 PM,Viatris (VTRS) Receives a Buy from Jefferies,TipRanks,/news/stocks/viatris-vtrs-receives-a-buy-from-jefferies-1033573002,positive,0.5900957584381104
7/24/2024 11:02:54 AM,Piper Sandler Reaffirms Their Hold Rating on Viatris (VTRS),TipRanks,/news/stocks/piper-sandler-reaffirms-their-hold-rating-on-viatris-vtrs-1033589582,neutral,0.7957625985145569
8/4/2024 12:00:00 PM,"Earnings week ahead: Disney, Duke Energy, Palantir, Shopify, Uber and more",Seeking Alpha,https://seekingalpha.com/news/4133349-earnings-week-ahead-disney-duke-energy-palantir-shopify-uber-plug-power-nikola-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9215457439422607
8/6/2024 11:52:20 AM,Viatris declares $0.12 dividend,Seeking Alpha,https://seekingalpha.com/news/4134692-viatris-inc-declares-0_12-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8892531991004944
8/7/2024 3:01:13 PM,What Wall Street expects from Viatris's earnings,Markets Insider Automation,/news/stocks/viatris-stock-price-quarter-earnings-preview-q2-1033652700,neutral,0.929730236530304
8/7/2024 4:20:57 PM,Viatris Q2 Earnings Preview: Another revenue miss in the cards?,Seeking Alpha,https://seekingalpha.com/news/4136198-viatris-q2-earnings-preview-another-revenue-miss-in-the-cards?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9539334177970886
8/8/2024 11:00:58 AM,"Viatris Non-GAAP EPS of $0.69 beats by $0.01, revenue of $3.8B beats by $60M",Seeking Alpha,https://seekingalpha.com/news/4136991-viatris-non-gaap-eps-of-0_69-beats-0_01-revenue-of-3_8b-beats-60m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.49279090762138367
8/8/2024 11:17:30 AM,"Earnings Summary: Viatris tops Q2 results, revises FY2024 outlook to reflect divestiture impact",Seeking Alpha,https://seekingalpha.com/news/4137038-earnings-summary-viatris-tops-q2-results-revises-fy2024-outlook-to-reflect-divestiture-impact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8546276688575745
8/8/2024 12:00:11 PM,Viatris in charts: Generics Q/Q net sales growth of ~6% reflects strong new product launch performances,Seeking Alpha,https://seekingalpha.com/news/4137105-viatris-in-charts-generics-qq-net-sales-growth-of-6-reflects-strong-new-product-launch-performances?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9563230872154236
8/8/2024 12:20:58 PM,Barclays Gives a Sell Rating to Viatris (VTRS),TipRanks,/news/stocks/barclays-gives-a-sell-rating-to-viatris-vtrs-1033661731,neutral,0.8919182419776917
8/8/2024 1:05:31 PM,Viatris Inc. Q2 Earnings Summary ,RTTNews,/news/stocks/viatris-inc-q2-earnings-summary-1033659896,neutral,0.7297752499580383
8/8/2024 1:55:36 PM,Viatris Sees 2024 Revenue Growth Of Approx. 2% On Divestiture-adj. Operational Basis - Update ,RTTNews,/news/stocks/viatris-sees-2024-revenue-growth-of-approx-2-on-divestiture-adj-operational-basis-update-1033660218,positive,0.7875779867172241
8/8/2024 2:26:51 PM,"Biggest stock movers today: UAA, WBD, MNST, and more",Seeking Alpha,https://seekingalpha.com/news/4136848-biggest-stock-movers-today-wbd-mnst-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9233841300010681
8/8/2024 2:45:00 PM,Viatris Inc Registered Shs hosts conference call for investors,Markets Insider Automation,/news/stocks/viatris_conference-1031432453,neutral,0.9491307139396667
8/8/2024 2:45:19 PM,Viatris hits seven-month high after Q2 beat,Seeking Alpha,https://seekingalpha.com/news/4137318-viatris-stock-gains-q2-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8716593980789185
8/9/2024 10:40:12 AM,Analyst Maintains Sell Rating on Viatris Citing Long-Term Revenue Concerns and Growth Challenges,TipRanks,/news/stocks/analyst-maintains-sell-rating-on-viatris-citing-long-term-revenue-concerns-and-growth-challenges-1033669125,negative,0.9499253034591675
8/9/2024 3:13:05 PM,74 S&P 500 stocks that can beat the cash yield - BofA,Seeking Alpha,https://seekingalpha.com/news/4138195-74-sp-500-stocks-that-can-beat-the-cash-yield-bofa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6393481492996216
8/15/2024 6:22:35 PM,"Glenview Capital's Q2 moves include selling Broadcom after just one quarter, exiting Meta",Seeking Alpha,https://seekingalpha.com/news/4140722-glenview-capitals-q2-moves-include-selling-broadcom-after-just-one-quarter-exiting-meta?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9504584074020386
9/6/2024 12:39:58 PM,"Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma",Seeking Alpha,https://seekingalpha.com/news/4147644-organon-stock-downgraded-jp-morgan?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8114075064659119
10/2/2024 1:47:37 PM,Gilead signs deals with six drugmakers for generic lenacapavir,Seeking Alpha,https://seekingalpha.com/news/4155488-gilead-signs-deals-with-six-drugmakers-for-generic-lenacapavir?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9220970273017883
10/7/2024 8:41:53 PM,"Novo Nordisk, Viatris settle patent dispute over Ozempic, Wegovy: report",Seeking Alpha,https://seekingalpha.com/news/4156843-novo-nordisk-viatris-settle-patent-dispute-over-ozempic-wegovy-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8707386255264282
10/9/2024 11:49:10 AM,U.S. government to release preliminary list for pilot Medicare program offering generics under $2 - report,Seeking Alpha,https://seekingalpha.com/news/4157219-us-government-to-release-preliminary-list-for-pilot-medicare-program-offering-generics-under-2-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8746735453605652
10/9/2024 1:13:49 PM,Viatris: EFFEXOR Meets Primary And All Secondary Efficacy Endpoints In Japan - Quick Facts ,RTTNews,/news/stocks/viatris-effexor-meets-primary-and-all-secondary-efficacy-endpoints-in-japan-quick-facts-1033831224,positive,0.8511783480644226
10/15/2024 12:16:19 PM,Viatris: Promising Financial Outlook with Strategic Share Repurchase and Low Valuation Potential,TipRanks,/news/stocks/viatris-promising-financial-outlook-with-strategic-share-repurchase-and-low-valuation-potential-1033847580,positive,0.9454500675201416
10/16/2024 9:33:28 PM,"Viatris to market Lexicon's sotagliflozin outside of US, Europe",Seeking Alpha,https://seekingalpha.com/news/4167676-viatris-to-market-lexicons-sotagliflozin-outside-of-us-europe?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6619526147842407
10/28/2024 9:01:32 AM,"Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Viatris (VTRS) and Syndax Pharmaceuticals (SNDX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-hca-healthcare-hca-viatris-vtrs-and-syndax-pharmaceuticals-sndx-1033901232,neutral,0.9072921276092529
11/4/2024 5:47:51 AM,"Earnings week ahead: O, PLTR, QCOM, SQ, AMC, PARA, LCID, RIVN, WBD, and more",Seeking Alpha,https://seekingalpha.com/news/4234003-earnings-week-ahead-o-pltr-qcom-sq-amc-para-lcid-rivn-wbd-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9318290948867798
11/5/2024 1:29:30 PM,Viatris declares $0.12 dividend,Seeking Alpha,https://seekingalpha.com/news/4248018-viatris-declares-012-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8892531991004944
11/6/2024 8:24:19 AM,Viatris (VTRS) Receives a Sell from Barclays,TipRanks,/news/stocks/viatris-vtrs-receives-a-sell-from-barclays-1033960556,neutral,0.6470100283622742
11/6/2024 8:16:52 PM,Viatris Q3 Earnings Preview: Focus on upcoming product launches and EBITDA growth,Seeking Alpha,https://seekingalpha.com/news/4257321-viatris-q3-earnings-preview-focus-on-upcoming-product-launches-and-ebitda-growth?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8882530927658081
11/7/2024 12:02:03 PM,"Viatris Non-GAAP EPS of $0.75, revenue of $3.8B",Seeking Alpha,https://seekingalpha.com/news/4260153-viatris-non-gaap-eps-of-0_75-revenue-of-3_8b?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9144965410232544
11/7/2024 12:11:14 PM,"Earnings Snapshot: Viatris tops Q3 estimates, reaffirms FY2024 revenue outlook, lowers profit",Seeking Alpha,https://seekingalpha.com/news/4260174-earnings-snapshot-viatris-tops-q3-estimates-reaffirms-fy2024-revenue-outlook-lowers-profit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.95827716588974
11/7/2024 1:09:45 PM,Viatris in charts: Revenue declines across product categories and markets in Q3,Seeking Alpha,https://seekingalpha.com/news/4260529-viatris-in-charts-revenue-declines-across-product-categories-and-markets-in-q3?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9713186621665955
11/7/2024 1:17:26 PM,"Viatris Inc. Q3 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/viatris-inc-q3-profit-decreases-but-beats-estimates-1033969612,negative,0.966273844242096
11/7/2024 2:55:15 PM,Early notable gainers among liquid option names on November 7th,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-november-7th-1033972925,positive,0.8915655016899109
11/7/2024 3:42:14 PM,Viatris nears 11-month high after Q3 beat,Seeking Alpha,https://seekingalpha.com/news/4261515-viatris-stock-jumps-after-q-3-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8214934468269348
11/8/2024 4:51:09 AM,Viatris Inc. Reports Strong Q3 2024 Performance,TipRanks,/news/stocks/viatris-inc-reports-strong-q3-2024-performance-1033979525,positive,0.9489314556121826
11/8/2024 9:37:56 AM,Viatris Underperform Rating: Limited Growth Prospects and Conservative Capital Allocation Strategy,TipRanks,/news/stocks/viatris-underperform-rating-limited-growth-prospects-and-conservative-capital-allocation-strategy-1033981542,negative,0.957758903503418
11/8/2024 12:22:49 PM,Viatris price target raised to $12 from $11 at Barclays,TipRanks,/news/stocks/viatris-price-target-raised-to-12-from-11-at-barclays-1033983102,positive,0.9433994889259338
11/22/2024 11:26:58 AM,Viatris fined £1.5M for failure to comply with CMA order,Seeking Alpha,https://seekingalpha.com/news/4320334-viatris-fined-15m-for-failure-to-comply-with-cma-order?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9619389772415161
12/6/2024 12:23:24 PM,Piper Sandler Sticks to Its Hold Rating for Viatris (VTRS),TipRanks,/news/stocks/piper-sandler-sticks-to-its-hold-rating-for-viatris-vtrs-1034108579,neutral,0.8117388486862183
12/6/2024 1:02:00 PM,Viatris price target raised to $14 from $13 at Piper Sandler,TipRanks,/news/stocks/viatris-price-target-raised-to-14-from-13-at-piper-sandler-1034108881,positive,0.9446036219596863
12/6/2024 10:48:06 PM,Viatris Elects Directors and Amends Stock Plan at Meeting,TipRanks,/news/stocks/viatris-elects-directors-and-amends-stock-plan-at-meeting-1034110199,neutral,0.9392999410629272
12/17/2024 1:50:22 PM,"Analysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Airsculpt Technologies, Inc. (AIRS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-and-airsculpt-technologies-inc-airs-1034147142,neutral,0.9122058153152466
12/18/2024 12:20:28 PM,Viatris announces publication of CARE study results,TipRanks,/news/stocks/viatris-announces-publication-of-care-study-results-1034151775,neutral,0.9000450372695923
12/18/2024 1:45:18 PM,Viatris Reports Phase 2b CARE Study Data For Cenerimod - Quick Facts ,RTTNews,/news/stocks/viatris-reports-phase-2b-care-study-data-for-cenerimod-quick-facts-1034150529,neutral,0.7923531532287598
12/20/2024 6:08:07 PM,UBS says ‘underweight the names with high China exposure’,Seeking Alpha,https://seekingalpha.com/news/4389391-ubs-says-underweight-the-names-with-high-china-exposure?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7156683802604675
12/23/2024 3:50:25 PM,Viatris receives FDA warning letter for 11 drugs made at India plant,Seeking Alpha,https://seekingalpha.com/news/4390132-viatris-receives-fda-warning-letter-11-drugs-made-india-plant?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5870209336280823
12/24/2024 11:50:08 AM,"Viatris confirms receipt of warning letter, import alert for India facility",TipRanks,/news/stocks/viatris-confirms-receipt-of-warning-letter-import-alert-for-india-facility-1034171279,neutral,0.6310263872146606
12/24/2024 11:55:08 AM,Viatris doesn’t see FDA warning impacting current 2024 financial guidance,TipRanks,/news/stocks/viatris-doesn-t-see-fda-warning-impacting-current-2024-financial-guidance-1034171276,neutral,0.7268891334533691
1/7/2025 2:55:27 PM,Argus Research Keeps Their Hold Rating on Viatris (VTRS),TipRanks,/news/stocks/argus-research-keeps-their-hold-rating-on-viatris-vtrs-1034201788,neutral,0.9317640066146851
